Official Title : A Phase 1 Open Label, Dose -Escalation Clinical Trial to Evaluate the Safety and 
Immunogenicity of a Trivalent Virus -Like Particle (VLP) Encephalitis Vaccine, VRC -WEVVLP073 -00-VP, in 
Healthy Adults  
 
ClinicalTrials.gov Identifier : [STUDY_ID_REMOVED]  
 
Document Type : 
• Redacted Study Protocol, including Letters of Amendment (Statistical Analysis Considerations 
located in Section 6 of the  Protocol)  
• Redacted IRB -approved Version 2.0 Informed Consent (dated March 12, 2019)  
 
Document/Date : 
• Protocol Version 1.0: January 9 , 2019 
• Protocol Version 1.0, Letter of Amendment #1: March 12, 2019  
• Protocol Version 1.0, Letter of Amendment #2: April 23, 2019  
• Protocol Version 1.0, Letter of Amendment  #3: October 24, 2019  
•  Version 2.0 IRB -approved Informed Consent  (dated March 12, 2019 with March 18, 2019 IRB -
approval)  
 
Version 1.0 
January 9, 2019 
   
 
VACCINE RESEARCH CENTER  
Protocol VRC 313 
 
A PHASE 1 OPEN LABEL , DOSE-ESCALATION CLINICAL TRIAL TO EVALUATE THE 
SAFETY  AND IMMUNOGENICITY OF A TRIVALENT VIRUS-LIKE PARTICLE (VLP)  
ENCEPHALITIS  VACCINE , VRC-WEVVLP073 -00-VP,  IN HEALTHY ADULTS  
 
 
Vaccine Provided by  
National Institute of Allergy and Infectious Diseases (NIAID)  
Vaccine Research Center (VRC)  
Bethesda, Maryland  
  
Clinical Trial Sponsored by  
National Institute of Allergy and Infectious Diseases (NIAID)  
Vaccine Research Center (VRC)  
Bethesda, Maryland  
BB-IND 11738 – held by VRC, NIAID, NIH 
  
Clinical Trial Management  
Leidos Biomedical Research, Inc.  
Frederick, Maryland, USA 
 
Protocol  Chair s 
Julie Ledgerwood, D.O.  
Cristina A. Carter, M.D. 
VRC, NIAID, NIH  
Bethesda, MD 20892 
 Clinical Research Site Principal Investigator: Srilatha Edupuganti, MD; MPH    IRB Initial Review Date:  February 20, 2019   
Confidentiality Statement  
This document is confidential and is to be distributed for review only to investigators, potential 
investigators, consultants, study staff, and applicable independent ethics committees or institutional review boards. The contents of this document shall not be disclosed to others without written authorization from NIAID (or others, as applicable), unless it is necessary to obtain informed 
consent from potential study subjects.  
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 2 of 66 
 
 Statement of Compliance  
The trial will be cond ucted in compliance with the protocol, the applicable regulatory 
requirements including but not limited to the United States (US) Code of Federal Regulations 
(CFR) applicable to clinical studies (45 CFR 46, 21 CFR including parts 50 and 56 concerning informed consent and Institutional Review Board (IRB)/Ethics Committee (EC) regulations, and 21 CFR 312 concerning Investigational New Drug (IND) application), International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals  for Human Use 
(ICH) Good Clinical Practice (GCP) guidance, and the NIAID Clinical Terms of Contract Award. Each site will hold a current Federal Wide Assurance (FWA) issued by the Office for Human Research Protections for federally funded research. Completion of Protection of Human Subjects Training will be required for all study personnel in accordance with National Institutes 
of Health (NIH)  policy.  
 
   
 
   
 
   
 
   
 
   
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 3 of 66 
 
 PRINCIPAL INVESTIGATOR PROTOCOL SIGNATURE PAGE  
VRC 313 : A Phase 1 Open Label, Dose -Escalation Clinical Trial to Evaluate the Safety and 
Immunogenicity of a Trivalent Virus- Like Particle (VLP) Encephalitis Vaccine, VRC -
WEVVLP073-00- VP, in Healthy Adults.  
Sponsored by: Vaccine Research Center (VRC), National Institute of Allergy and Infectious 
Diseases (NIAID) National Institutes of Health (NIH)  
I, the Principal Investigator for the indicated VRC 313 Study Site, agree to conduct this study in 
full accordance with the provisions of this protocol and protocol amendments. I will comply with 
all requirements regarding the obligations of investigators as outlined in the Statement of 
Investigator (Form FDA 1572), which I have also signed. I agree to maintain all study documentation pertaining to the conduct of this study, including, but not l imited to, case report 
forms, source documents, consent forms, laboratory test results, and medication inventory records, for at least 2 years following submission of a United States Biologics License Application. If no marketing application is filed, or if the application is not approved, the records will be retained for two years after the investigation is discontinued and the US Food and Drug Administration is notified. No study records will be destroyed without prior authorization from VRC/NIAID. Publication of the results of this study will be governed by the VRC/NIAID policies. Any presentation, abstract, or manuscript will be made available by the investigators to 
VRC Leadership and to NIAID for review prior to submission.  
I have read and understand the information in this protocol and the Investigator’s Brochure and 
will ensure that all associates, colleagues, and employees assisting in the conduct of the study are informed about the obligations incurred by their contribution to the study.  
 
__________________________________                            ________________________  Name/Title of Principal Investigator    Study Site Name/Identifier  
  __________________________________                            ________________________ Signature of Princi pal Investigator                                         Date  
  
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 4 of 66 
 
 TABLE OF CONTENTS  
 
TABLE OF ABBREVIATIO NS .....................................................................................................8  
PRÉCIS  ……………………………………………………………….……………………….9  
1 INTRODUCTION  ......................................................................................................10  
1.1 Etiology, Epidemiology, and Disease Course ............................................................10  
1.2 Rationale for the Development of the WEVEE Vaccine  ............................................10  
1.3 Rationale for the Use of Aluminum–Based Adjuvant ................................................11  
1.3.1  Animal Experience with WEVEE VLP and  Aluminum-based Adjuvants .................11  
1.4 Previous Human Experience .......................................................................................12  
1.4.1  VRC -CHKVLP -59-00- VP (CHIK VLP) Vaccine and Other VLP Vaccines  ............12  
1.4.2  Human Experience with Other Alphavirus Vaccines .................................................13  
1.4.3  Previous Human Experience with Aluminum-based Adjuvants ................................13  
1.5 Rationale for Study Design  .........................................................................................14  
1.6 Assessment of Immunogenicity ..................................................................................14  
2 STUDY PRODUCTS  .................................................................................................14  
2.1 VRC -WEVVLP073-00-VP, Study Product ................................................................14  
2.2 VRC -GENMIX083 -AL-VP, Adjuvant .......................................................................14  
2.3 VRC -PBSPLA043-00-VP, Diluent ............................................................................14  
2.4 Preclinical Studies of VRC -WEVVLP073-00- VP .....................................................15  
3 STUDY OBJECTIVES  ..............................................................................................15  
3.1 Primary Objectives  .....................................................................................................15  
3.2 Secondary Objectives  .................................................................................................15  
3.3 Exploratory Objectives ...............................................................................................15  
4 STUDY DESIGN AND CLINICAL PROCEDURES  ...............................................15  
4.1 Study Population .........................................................................................................16  
4.1.1  Inclusion Criteria  ........................................................................................................16  
4.1.2  Exclusion Criteria  .......................................................................................................17  
4.2 Clinical Procedures And Evaluations .........................................................................18  
4.2.1  Pre-screening  ..............................................................................................................18  
4.2.2  Screening  ....................................................................................................................18  
4.2.3  Enrollment ..................................................................................................................19  
4.2.4  Randomization ............................................................................................................19  
4.2.5  Study Schedule ...........................................................................................................20  
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 5 of 66 
 
 4.2.6  Product Administration  ...............................................................................................21  
4.2.7  Safety Evaluations and Follow -up after Product Administration  ...............................22  
4.2.8  Blood Sample Collection  ............................................................................................22  
4.2.9  Concomitant Medications ...........................................................................................22  
4.3 Dose Escalation  ..........................................................................................................23  
4.4 Pausing and Resuming the Study ...............................................................................24  
4.4.1  Criteria for Pausing the Study .....................................................................................24  
4.4.2  Plan for Review of Pauses and Resuming the Study ..................................................24  
4.4.3  Dose -Limiting Toxicity  ..............................................................................................24  
4.5 Discontinuation of Product Administrations or Study Participation  ..........................24  
4.5.1  Discontinuation of Product Administrations ..............................................................24  
4.5.2  Discontinuation from Protocol Participation  ..............................................................25  
5 SAFETY AND ADVERSE EVENTS  ........................................................................25  
5.1 Adverse Events  ...........................................................................................................25  
5.2 Serious Adverse Events ..............................................................................................26  
5.3 Adverse Event Reporting to the IND Sponsor ...........................................................26  
5.3.1  IND Sponsor Reporting to the FDA ...........................................................................27  
5.4 Reporting to the Institutional Review Board  ..............................................................27  
5.4.1  Unanticipated Problems ..............................................................................................27  
5.4.2  Protocol Deviations ....................................................................................................28  
5.4.3  Non-Compliance .........................................................................................................28  
5.4.4  Expedited and Annual Reporting to the site IRB .......................................................29  
6 STATISTICAL CONSIDERATIONS  .......................................................................29  
6.1 Overview  .....................................................................................................................29  
6.2 Endpoints ....................................................................................................................29  
6.2.1  Primary Endpoints: Safety ..........................................................................................29  
6.2.2  Secondary Endpoints: Immunogenicity ......................................................................29  
6.2.3  Exploratory Endpoints: Immunogenicity ...................................................................29  
6.3 Sample Size and Accrual  ............................................................................................29  
6.3.1  Power Calculations for Safety  ....................................................................................30  
6.3.2  Sample Size Calculations for Immunogenicity  ..........................................................31  
6.3.3  Power for Comparison ................................................................................................31  
6.4 Statistical Analysis  ......................................................................................................31  
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 6 of 66 
 
 6.4.1  Analysis Variables  ......................................................................................................31  
6.4.2  Baseline Comparability  ..............................................................................................31  
6.4.3  Safety Analysis  ...........................................................................................................32  
6.4.4  Immunogenicity Analysis  ...........................................................................................32  
6.4.5  Missing Data  ...............................................................................................................32  
6.4.6  Interim Analyses of Immunogenicity .........................................................................33  
6.5 Randomization of Intervention Assignments .............................................................33  
7 PHARMACY PREPARATION AND ADMINISTRATION PROCEDURES  .........33  
7.1 Study Products ............................................................................................................33  
7.2 Study Product Presentation, Stability, and Storage ....................................................34  
7.2.1  Labels  ..........................................................................................................................34  
7.2.2  Stability  .......................................................................................................................34  
7.2.3  Storage  ........................................................................................................................34  
7.2.4  Deviatio ns in Temperatures  ........................................................................................34  
7.3 Preparation of Study Product for Administration .......................................................35  
7.3.1  Preparation of VRC-WEVVLP073-00- VP.................................................................35  
7.3.2  Preparation of VRC-WEVVLP073-00-VP plus Adjuvant .........................................36  
7.4 Study Product Administration  ....................................................................................37  
7.5 Study Product Accountability .....................................................................................37  
7.5.1  Documentation ............................................................................................................37  
7.5.2  Disposition ..................................................................................................................37  
8 HUMAN SUBJECT PROTECTIONS AND ETHICAL OB LIGATIONS ................37  
8.1 Institutional Review Board  .........................................................................................37  
8.2 Subject Recruitment  and Randomization  ..................................................................38  
8.2.1  Participation of Children  .............................................................................................38  
8.2.2  Participation of Site Employees  ..................................................................................38  
8.3 Informed Consent .......................................................................................................38  
8.4 Subject Confidentiality  ...............................................................................................38  
8.5 Risks and Benefits ......................................................................................................39  
8.5.1  Risks of the WEVEE Vaccine  ....................................................................................39  
8.5.2  Risks of Aluminum Hydroxide Suspension ...............................................................39  
8.5.3  Risks of Phosphate Buffered Saline ...........................................................................40  
8.5.4  Other Risks .................................................................................................................40  
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 7 of 66 
 
 8.5.5  Benefits  .......................................................................................................................40  
8.6 Plan for U se and Storage of Biological Samples ........................................................40  
8.6.1  Use of Samples, Specimens and Data  .........................................................................40  
8.6.2  Storage and Tracking of Blood Samples and Other Specimens .................................41  
8.6.3  Disposition of Samples, Specimens and Data at Completion of the Protocol ............41  
8.6.4  Loss or Destruction of Samples, Specimens or Data ..................................................41  
8.7 Subject Compensa tion ................................................................................................41  
8.8 Safety Monitoring .......................................................................................................41  
8.8.1  Protocol Safety Review Team  ....................................................................................41  
9 ADMINISTRATIVE AND LEGAL OBLIGATIONS  ..............................................42  
9.1 Protocol Amendments and Study Termination...........................................................42  
9.2 Study Documentation and Storage .............................................................................42  
9.3 Data Collection and Protocol Monitoring...................................................................43  
9.3.1  Data Collection  ...........................................................................................................43  
9.3.2  Data Sharing Plan  .......................................................................................................43  
9.3.3  Source Documents ......................................................................................................43  
9.3.4  Protocol Monitoring Plan ...........................................................................................43  
9.4 Language  .....................................................................................................................43  
9.5 Policy Regar ding Research -Related Injuries  ..............................................................44  
9.6 Site Management  ........................................................................................................44  
10 REFERENCES  ...........................................................................................................45  
APPENDIX I:  STUDY INFORMED CONSENT FORM  ...........................................................47  
APPENDIX II:  CONTAC T INFORMATION  .............................................................................56  
APPENDIX III: SCHEDULE  OF EVALUATIONS  ....................................................................58  
APPENDIX IV: ASSESSM ENT OF RELATIONSHIP TO VACCINE AND  
GRADING SEVERITY OF ADVERSE EVENTS  ....................................................60  
 
TABLES 
Table 1: VRC 313 Vaccination Schema ........................................................................................16  
Table 2:  Probability of Events for Different Safety and Immunogenicity Scenarios 
within a Group (n=5) ..................................................................................................30  
Table 3:  95% Confidence Intervals for the True Rate At All Possible Observed Rates within a Group (n=5) ..................................................................................................30
 
Table 4:  Power (%) to Detect Difference in Response Rates between Two groups by 
Fisher’s Exact Test, Each Group of Size n=5  .............................................................31  
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 8 of 66 
 
 TABLE OF ABBREVIATIONS  
Abbreviation  Term   
AE adverse e vent 
ALT  alanine aminotransferase  
AoU  assessment of understanding  
Alum  aluminum hydroxide suspension  
BMI  body mass index  
CBC  complete blood count  
cGMP  Current Good Manufacturing Practices  
EEEV  Eastern Equine Encephalitis Virus  
ELISA  enzyme -linked immunosorbent assay  
FDA  Food and Drug Administration  
GCP  Good Clinical Practices  
GLP  Good Laboratory Practices  
GMT  Geometric Mean Titer  
HIV Human Immunodeficiency V irus 
IB Investigator’s Brochure  
ICF Informed Consent Form  
IM intramuscular  
IND investigational new drug application  
IRB Institutional Review Board  
LIMS  Laboratory Information Management System  
MedDRA  Medical Dictionary for Regulatory Activities  
MAC -ELISA  monoclonal antibody -based antigen -capture  enzyme -linked immunosorbent assay  
NIAID  National Institute of Allergy and Infectious Diseases  
NIH National Institutes of Health  
NHP  non-human primate  
NSAID  nonsteroidal anti -inflammatory drug  
PBS phosphate buffered saline  
PI Principal Investigator  
PSRT  Protocol Safety Review Team  
RNA  ribonucleic acid  
SAE  serious adverse event  
SAS Statistical Analysis System  
SUSAR  serious and unexpected suspected adverse reaction  
ULN  upper limit of normal  
UP unanticipated p roblem  
VCMP  Vaccine Clinical Material Program  
VEE V Venezuelan  Equine Encephalitis Virus  
VITL  Vaccine Immunology Testing Laboratory  
VLP  virus-like particles  
VRC  Vaccine Research Center  
WBC  white blood cell  
WEEV  Western Equine Encephalitis Virus  
WEVEE  Western, Eastern and Venezuelan Equine Encephalitis  
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 9 of 66 
 
 PRÉCIS  
VRC 313:  A Phase 1 Open Label, Dose- Escalation Clinical Trial to Evaluate the Safety and 
Immunogenicity of a Trivalent Virus -Like Particle (VLP) Encephalitis Vaccine, VRC -
WEVVLP073 -00-VP, in Healthy Adults.  
Study  
Design:  This is a Phase I, randomized, open-label, dose-escalation study to examine the dose, 
safety, tolerability, and immunogenicity of VRC- WEVVLP073 -00-VP (WEVEE)  alone 
or with alum adjuvant in a 2-product administration regimen. The trivalen t encephalitis 
vaccine VRC- WEVVLP073 -00-VP is composed of Western equine encephalitis  (WEE) , 
Eastern equine encephalitis (EEE), and Venezuelan equine encephalitis  (VEE) VLPs.  
The hypotheses are that the vaccine is safe and will induce immune responses to all three 
alphaviruses.   
The p rimary  objectives are  to evaluate the safety and tolerability of the investigational 
vaccine at three doses administered alone or with adjuvant in healthy adults. Secondary 
objectives relate  to immunogenicity of the investigational vaccine  and dosing regimen.  
Study  
Product : The investigational VRC- WEVVLP073 -00-VP vaccine was developed by the Vaccine 
Research Center (VRC) and is composed of a mixture of WEE, EEE, and VEE VLPs in a 
1:1:1 mass ratio filled into single -dose vials at a concentration of 78 mcg/mL.  
Adjuvant is an aluminum hydroxide suspension (alum) provided in a sterile, pyrogen- free 
suspension at a concentration of 5 mg/mL in 3 mL glass vials filled to 0.7 ± 0.10 mL. The 
alum dose is 500 mcg and will be mixed  during prepar ation of each vaccine dose . 
VRC- PBSPLA043 -00-VP is sterile phosphate buffered saline (PBS),  1.2 mL per vial 
prepared for human injection as a diluent. 
 
Subjects:  Up to 40 h ealthy  adult s ages 18 to 50 . 
 
Study Plan:  Eligible subjects will be randomized to receive WEVEE alone or WEVEE plus alum in each dose group. The product will be administered as an intramuscular (IM) injection in 
the deltoid muscle via needle and syringe on Day 0  and Week 8.  For all Groups, solicited 
reactogenicity will be evaluated using a 7 -day diary card. Assessment of vaccine safety 
will include clinical observation and monitoring of hematological and chemical parameters at clinical visits throughout the study. Safety dose escalation reviews will 
occur to ensure the safety data support proceeding to the higher doses. 
The study requires about 9 clinic visits and 2 telephone follow- up contacts after each 
product administration. The study schema is  shown below. 
 
VRC 313 Vaccination Schema  
Group  Subjects  Dose  Day 0 Week 8  
1 5 6 mcg  WEVEE  WEVEE  
2 5 WEVEE + alum  WEVEE + alum  
3 5 30 mcg WEVEE  WEVEE  
4 5 WEVEE + alum  WEVEE + alum  
5 5 60 mcg WEVEE  WEVEE  
6 5 WEVEE + alum  WEVEE + alum  
Total* 30 *Up to 10 subjects over target accrual  are permitted to be 
allocated to any group if needed for additional safety or 
immunogenicity evaluations.  
 
Study  
Duration:  Subjects will be evaluated for 36  weeks following the first vaccine administration .
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 10 of 66 
 
 1 INTRODUCTION  
The Dale and Betty Bumpers Vaccine Research Center (VRC), National Institute of Allergy and 
Infectious Diseases  (NIAID), National Institutes of Health (NIH)  in Bethesda, Maryland,  is 
dedicated to translating the latest knowledge of disease pathogenesis and  immunology into new 
vaccine strategies to provide safe and effective means to prevent and control infectious diseases.  
Western Equine E ncephalitis Virus (WEE V), Eastern Equine E ncephalitis  Virus (EEEV ), and 
Venezuelan Equine E ncephali tis Virus (VEE V) are transmitted by mosquitoes and can caus e an 
acute infection associated with severe morbidity that can persist for several weeks, months or even years  [1].  T hese encephalitic a lphaviruses are classified as Category B bioterrorism agents 
by the Centers for Disease Control and Prevention (CDC) and the need to develop effective 
vaccines and therapeutics against these organisms is considered a high priority [ 2].  Alphaviruses 
are of significant interest for tactical weapons development (biological warfare) due to  their 
relative stability and highly infectivity  to humans in  aerosol  form .  The viruses can be 
inexpensively produced in large quantities and can yield either incapacitating or lethal infections.  
Public health demands and preventive bioterrorism measures support the need for a safe and 
immunogenic vaccine.  The product, VRC -WEVVLP073-00- VP (or WEVEE) , is a trivalent 
vaccine intended to elicit broad spectrum protection against WEE V, EEEV and VEEV exposure.  
The study is designed as a first-in-human Phase I  study to evaluate the dose, safety, tolerabilit y 
and immunogenicity of the WEVE E Vaccine.  
1.1 Etiology, Epidemiology , and Disease Course  
WEEV, EEEV and VEEV  belong to the Alphavirus  genus of the Togaviridae family and have a 
positive sense, single-stranded ribonucleic acid (RNA) genome encoding structural and non-
structural proteins.  The non- structural genes inclu de replication proteins RNA polymerase and 
helicase.  Structural genes include the capsid, protein 6K and envelope proteins ( E1, E2 and E3). 
These viruses are transmitted in nature through infected mosquitoes, widely circulate in North, Central and South America, causing periodic epizootics [ 1].  Highly pathogenic in animals and 
humans, the pathology of these viruses is often associated with encephalitis and other 
neurological manifestations [ 1, 3].  Acute clinical manifestations include  fever, headache, 
lymphopenia, myalgia and ma laise.  Severe neurological disease including fatal encephalitis can 
also occur in humans, with e stimated case- fatality rates  of ≤1% for VEE V, 8-15% for WEE V, 
and 30- 70% fo r EEEV [ 4, 5].  There is no  effective antiviral treatment for any of these 
encephalic viruses, so treatment remains supportive [ 3]. 
Alphavirus infection can be confirmed by the isolation of nucleic acid or virus  in serum or spinal 
fluid .  The best method for virus identification is by IgM antibody -capture enzyme-linked 
immunosorbent assay (ELISA)  using monoclonal antibody- based antigen -capture (MA C-
ELISA) in the acute-phase.  Other detection  methods includes the seroconversion of individuals 
between acute and convalescent phases and the isolation of virus from the brain following fatal 
encephalitis  [3, 6, 7 ].
  
1.2    Rationale for the Development of the W EVEE Vaccine  
Alphavirus es have been responsible for multiple epidemics in various parts of the world.  There 
is no effective antiviral treatment or licensed vaccine for any of these encephalitic arboviruses  
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 11 of 66 
 
 and treatment is  with supportive measures only.  Additionally, prevention of vir al infectio n is of 
particular interest because of the potential use of these viruses as biological weapon s.   
VLPs are multiprotein structures that mimic the organization and conformation of authentic 
native viruses without the viral genome.  Due to the absence of the viral genome, the VLP s 
cannot replicate.   VLPs contain viral surface proteins that present repetitive linear and 
conformational epitopes capable of eliciting strong T and B cell immune responses and therefore, 
are useful as vaccines.   
VRC previously developed VRC- CHKVLP059 -00-VP, a Chikungunya virus (CHIK V) VLP 
vaccine.  Th is vaccine demonstrated induction of neutralizing antibodies and protection against 
CHIKV  infection by percutaneous exposure in a rhesus macaque model [ 8].  Under IND 14907, 
a Phase 1 clinical trial demonstrated that the vaccine was safe and highly immunogenic in healthy adults  [9] and a Phase 2 clinical trial in CHIKV -endemic regions is pending final 
analysis . 
VRC -WEVVLP073-00- VP (or WEVEE) is a trivalent WEE,  EEE, and VEE  VLP vaccine 
produced by the same methods as the CHIK V VLP vaccine and is  intended to elicit broad 
spectrum protection against targeted alphaviruses.  
1.3 Rationale for the Use of  Aluminum –Based Adjuvant  
Adjuvants improve the immune response to many vaccines [ 10, 11].  The most common 
aluminum-based adjuvants includes aluminum hydroxide, aluminum phosphate, alum  (potassium 
aluminum sulfate), or mixed aluminum salts [12, 13].  Several phenomena contribute to the 
effect of alumi num hydroxide based adjuvants: a ‘repository effect’ which  occurs when the 
antigens aggregate on the adjuvant particle and are deposited t o the immune cell for long 
duration to induce immune responses, a pro-phagocytic effect, and possibly the activation of the 
pro-inflammatory  nucleotide like receptor protein 3 (NLRP3) dependent pathway s [13].  
Aluminu m-based ad juvants often improve humoral and innate responses and may lead to 
increased antibody titers, rapid induction of responses, reduction in size or frequency of doses, increased breadth of responses to overcome pathogen diversity, induction of long- lasting 
immune memory responses, and induction of response to overcome poor immune systems in 
elderly and young children [ 14-17].  Alu minum is generally well tolerated , and adjuvants have a 
demonstrated safety profile over more than six decades  of use [ 14, 15]. 
1.3.1 Animal Experience with WEVEE VLP and Aluminum -based Adjuvants  
Preclinical studies were performed to evaluate the immunogenicity of the trivalent WEVEE VLP 
vaccines alone and with aluminum hydroxide adjuvant in rabbits and mice.  
Mice (n=5/dose) received two intramuscular ( IM) injections with WEVEE alone or WEVEE plus 
alum on days 0 and 28.  Antibody responses against WEVEE VLP were evaluated by ELISA 
every 2 weeks up to 16 weeks.  Immune responses were induced faster  with adjuvanted VLPs 
than unadjuvanted VLPs, and adjuvant effect was observed after priming immunization. WEVEE at 15 mcg + alum generated higher antibody responses than other doses of WEVEE with alum.   Description of the rabbit and non-human primate (NHP) studies can be found in the 
Investigator’s Brochure (IB).  
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 12 of 66 
 
 1.4 Previous Human Experience  
There is no human experience w ith VRC -WEVVLP0 73-00- VP.  Previous human experience 
with similar products and with aluminum hydroxide  adjuvants are described below. 
1.4.1 VRC- CHKVLP -59-00- VP (CHIK VLP) Vaccine and  Other VLP Vaccines  
VRC -CHKVLP059 -00-VP:  The CHIKV VLP vaccine was assessed in  a Phase 1 open- label, 
dose- escalation study (VRC 311, [STUDY_ID_REMOVED]) [ 9].  A ll injections were well tolerated with no 
reported arthralgia or fever after vaccination and no reported  serious adverse events (SAEs).  
Solicited reactogenicity parameters  were either none or mild; 36% of vaccinees reported mild 
local reactogenicity and  40% reported mild systemic reactogenicity at least once following 
vaccination [ 9].  Neutralizing antibodies were detected in all subjects  by 4 weeks after the second 
dose.  A significant boost occurred after the third vaccination in all dose groups.  Neutralization 
titers of vaccine recipients reached levels comparable to those reported after natural infection, 
suggesting a potentially durable protective response to the vaccine [ 9].  Antibodies were detected 
by ELISA in 80-100% of subjects in all three dose groups and geometric mean titers (GMT) 
were not significantly different between the groups except at week 24.  S tudy results fo und no 
significant difference in group GMT 4 weeks after the second dose compared to 4 weeks after the third dose. 
This alphavirus CHIKV VLP vaccine was advanced to Phase 2 clinical  evaluation in November 
2015 in protocol VRC 704 ([STUDY_ID_REMOVED]).  Between November 18, 2015 to October 20, 2016, 
400 subjects were randomly enrolled into two groups: CHIKV VLP vaccine (n = 201) or PBS placebo (n = 199). Of the 201 participants in the CHIKV VLP vaccine group, 192 received both 
vaccinations, and 180 completed the study to week 72. Of the 199 participants in the PBS 
placebo group, 192 received both placebo vaccinations, and 193 completed the study to week 72. 
The CHIKV VLP vaccine was well tolerated, with no SAE related to vaccine reported. For local 
reactog enicity, including pain/tenderness, swelling or redness, 64 (32%) vaccine recipients 
reported any local symptom, rated as mild or moderate in severity. For systemic reactogenicity, 
including malaise, myalgia, headache, chills, nausea, joint pain and temperature, 87 (44%) 
vaccine recipients reported any systemic symptom, rated as mild or moderate in severity. One 
vaccine recipient (0.5%) experienced a headache graded as severe after the second vaccination. In comparison to placebo, the only significant diffe rence in local reactogenicity was 
pain/tenderness at the injection site (p -value = 0.005) and there were no significant differences 
observed in other solicited systemic reactogenicity parameters in vaccine recipients.  
Overall, 16 mild -to-moderate AEs evaluated as potentially related to the study product occurred 
in 11 subjects (neutropenia, bradycardia, hypotension, viral infection, rash, chest pain, dry lips, 
light headedness, fever, myalgia, gastroenteritis, abdominal pain, anemia, alanine aminotransferase increase, and two hematomas. Of these, AEs (75%) occurred in 8 subjects in 
the vaccine group, and four AEs (25%) occurred in three subjects in the placebo group. All 
potentially related adverse events resolved without clinical sequelae.    
Other VLP Vac cines :  VLP s are considered highly immunogenic and are known to elicit high ly 
neutralizing antibody titers .  The FDA has approved several prophylactic VLP vaccines 
including hepatitis B vaccines (Engerix® and Recombivax HB®, GlaxoSmithKline and Merck, 
respectively) and human papilloma virus (HPV) vaccines (Cervarix® and Gardasil®, 
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 13 of 66 
 
 GlaxoSmithKline and Merck, respectively).  Several other VLP vaccine candidates, such as 
vaccines for influenza, Norwalk and parvovirus, are in pre- clinical or Phase I testing [ 18, 19].  
1.4.2 Human Experience with Other Alphavirus Vaccines  
While there are inactivated vaccines for EEE V and WEE V, and live- attenuated and inactivated 
VEEV vaccines for veterinary use, there are no licensed human vaccines.  Human i nvestigational 
alphavirus vaccines have been used for protection of laboratory workers and other at- risk 
personnel under FDA  IND applications [ 20].  A live -attenuated VEE V vaccine was develo ped by 
the U .S. Army and tested  in 821 laboratory workers ; minor side- effects (malaise, headache, 
fever, chills, myalgia, sore throat, nausea, arthralgia, anorexia, vomiting, diarrhea, erythema, rash, urticarial, vasovagal response) were noted in 23% of vaccines  recipients and no long term 
sequelae were reported.  At the end  of the study, the prime -boost regimen of the live -attenuated 
VEE V vaccine prime (TC-83) followed by the inactivated VEE V vaccine boost (C-84) induced 
long- lasting immune response; however, the investigator s concluded that a more immunogenic, 
less reactogenic, single -dose vaccine is needed  [21]. 
Immunologic interference was revealed in sequential or same-day administration of previous generation s of inactivated and live-attenuated alphavirus vaccines in animal models and in 
humans [ 22-25].  In a retrospective data analysis study with 766 volunteers immunized through a 
special immunization program at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), subjects who received inactivated EEE V and WEEV vaccines before the 
live-attenuated VEE V vaccine had significantly lower rates of antibody response than subjects 
receiving VEE V vaccine before EEE V and WEEV vaccines (66.7% and 80.6%, respectively, 
p=0.026) [ 24].  Similar findings were reported for the same- day/different arm administration of 
inactivated EEE V and WEEV vaccines in a cohort of 1401 volunteers immunized through the 
same program .  The overall primary response rate for EEE V vaccines was 66% and for WEEV 
vaccine was 42%  [25]. 
1.4.3 Previous Human Experience w ith Aluminum -based Adjuvants  
Aluminum adjuvants have been used in vaccines for many decades and with a demonstrated safety profile  [26].  Aluminum is the most common adjuvant used in human vaccines licensed by 
the FDA  [27, 28].  Aluminum- containing vaccines have been associated with erythema, 
subcutaneous nodules, contact hypersensitivity, granulomatous inflammation  [26, 29].  A 
specific limitation  is neurotoxicity in patients with decreased renal function [ 27].  
Aluminum-based adjuvants promote strong humoral immune responses, and therefore, are 
incorporated in vaccines against diseases where neutralizing antibodies are required for 
protection such as diphtheria, tetanus and hepatitis B [ 17].  The licensed HPV VLP vaccines, 
Gardasil (Merck & Co, Inc.) and Cervarix (GlaxoSmithKline), have alum inum in the 
formulations at 0.5 mg of aluminum hydroxyphosphate sulphate per dose and 0.5 m g of 
aluminum hydroxide per dose, respectively [ 18].  
As per 21 CFR part 610.15, the amount of aluminum in biological products cannot exceed 0.85 
mg/dose.  The amount of aluminum in vaccines currently licensed in the US ranges from 0.125-
0.85 mg/dose [ 28].  
Based on the FDA regulations, experience with HPV VLP vaccines and 
VRC pre -clinical data, VRC plans to use 0.5 mg/dose of alum inum hydroxide adjuva nt in this 
Phase 1 study.  
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 14 of 66 
 
 1.5    Rationale for Study Design  
In this Phase I dose- escalation study, each subject will receive an IM injection via needle and 
syringe at Day 0 and Week 8 .  Doses of 6, 30, and 60 mcg of VRC -WEVVLP073 -00-VP will be 
evaluated either alone or with aluminum hydroxide adjuvant.  Th e doses and dosing regimens 
were selected based on the results of preclinical studies in NHPs  (WEVEE Investigator’s 
Brochure and [ 8]), and results of VRC studies with the CHIKV VLP vaccine, VRC -CHKVLP -
59-00-VLP, in animals and in humans [ 8, 9].  Similar dosing in ranges of 10 -60 mcg of VLP per 
injection and a dosing regimen of three IM injections is used for licensed VLP vaccines against 
hepatitis B and HPV [ 18, 30].  
1.6    Assessment of Immunogenicity  
In this protocol, specimens to evaluate immunogenicity will be taken at baseline and at specified time points.  The primary immunogenicity timepoint is  4 weeks after the second vaccination .  
Measurements of WEVEE -specific humoral immune responses will be assessed by neutr alization 
antibody assays.  ELISA and other exploratory assays to assess humoral immune responses may be performed with stored samples .  Research samples for immunogenicity assays will be 
processed at the site and  sent directly to the contracted testing la boratory, Battelle, in Columbus, 
OH.  Exploratory immunogenicity assays may also be performed by VRC or contract 
laboratories, or by other research collaborators.  
2 STUDY PRODUCTS   
The s tudy products are manufactured under current Good Manufacturing Practices (c GMP) . 
Brief description of the study products are provided in the next sections; for detailed descriptions, please refer to the IB.   
2.1    VRC-WEVVLP073 -00-VP, Study Product   
VRC-WEVVLP073-00-VP (WEVEE) is a sterile, aqueous, buffered solution composed of a 
1:1:1 ratio (based on mass) of WEE, EEE, and VEE drug substances to meet a target concentration of 90 mcg/mL (final concentration = 78 mcg/mL).  Product is filled into single-dose vials.  The formulation buffer consists of 0.8 mM Sodium Phosphate Monobasic 
Monohydrate, 9.3 mM Sodium Phosphate Dibasic Hetpahydrate, 50 mM Sodium Chloride, 5% 
Sucrose, 5% Sorbitol, and 0.05% Poloxamer  188 at pH 7.8.   
2.2    VRC-GENMIX083 -AL-VP, Adjuvant   
VRC -GENMIX083 -AL-VP or  Aluminum Hydroxide Suspension (alum, adjuvant) is a sterile, 
pyrogen -free, suspension filled into glass vials at a nominal fill volume of 0.7 mL ± 0.10 mL to 
allow withdrawal of 0.5 mL.  Aluminum concentration is 5 ± 1 mg/mL.   
2.3    VRC-PBSPLA043-00 -VP, Diluent  
VRC -PBSPLA043-00- VP consists of sterile phosphate buffered saline (PBS) at pH 7.2, 
aseptically filled at 1.2 mL in a 3 mL glass vial for single use.   
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 15 of 66 
 
 2.4    Preclinical Studies of VRC-WEVVLP073 -00-VP  
Details on preclinical studies conducted with VRC-WEVVLP073-00- VP alon e or with adjuvant 
can be found in the IB.  
3 STUDY OBJECTIVES  
3.1    Primary Objectives  
• To evaluate the safety and tolerability of VRC -WEVVLP073-00- VP in healthy adults 
when administered IM by needle and syringe at a dose of 6 mcg, 30 mcg or 60 mcg 
without adjuvant. 
• To evaluate the safety and tolerability of VRC -WEVVLP073-00-VP in healthy adults 
when administered IM by needle and syringe at a dose of 6 mcg, 30 mcg or 60 mcg 
with adjuvant. 
3.2    Secondary  Objectives  
• To evaluate the humoral immunogenicity of VRC-WEVVLP073-00- VP without 
adjuvant at 4 weeks after the last product administration by vi rus-specific 
neutralization assays.  
• To evaluate the humoral immunogenicity of VRC-WEVVLP073-00- VP with  
adjuvant at 4 weeks after the last product administration  by virus- specific 
neutralization assays.  
3.3    Exploratory Objectives  
• To evaluate the immunogeni city of VRC -WEVVLP073 -00-VP without adjuvant at 
other timepoints throughout the study. 
• To evaluate the immunogenicity  of VRC -WEVVLP073 -00-VP with adjuvant at other 
timepoints throughout the study. 
4 STUDY DESIGN AND CLINICAL PROCEDURES  
This is a Phase I, randomized, open-label, dose- escalation study to examine the dose, safety, 
tolerability, and immune response to the WEVEE vaccine alone or with alum  adjuvant at three 
doses (6 mcg, 30 mcg, and 60 mcg) in healthy adults.   Eligible s ubject s will be randomized to 
WEVEE alone or WEVEE plus alum administration in each dose group.  The product will be 
administered IM in the deltoid muscle via needle and syringe at Day 0 and Week 8 in each dose group.  The hypothes es are that this vaccine will b e safe and elicit specific immune responses to 
WEE, EEE and VEE viruses.    
Group assignments and study s chema are shown below  in Table 1: 
 
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 16 of 66 
 
 Table 1: VRC 313 Vaccination Schema 
VRC 313 Vaccination Schema  
Group  Subjects  Dose  Day 0  Week 8  
1 5 
6 mcg  WEVEE  WEVEE  
2 5 WEVEE + alum  WEVEE + alum  
3 5 
30 mcg WEVEE  WEVEE  
4 5 WEVEE + alum  WEVEE + alum  
5 5 
60 mcg WEVEE  WEVEE  
6 5 WEVEE + alum  WEVEE + alum  
Total * 30 *Up to 10 subjects over target accrual  are permitted to be allocated to 
any group for additional safety or immunogenicity evaluations.  
4.1    Study Population  
All inclusion and exclusion criteria must be met  for eligibility .  
4.1.1 Inclusion Criteria  
A subject  must meet all of  the following criteria : 
1. Age 18 to 50 years  
2. Available for cli nical follow-up through 36 weeks after randomization 
3. Able to provide proof of identity to the satisfaction of the study clinician completing the 
enrollment process 
4. Able and willing to complete the informed consent process 
5. Willing to donate blood for sample storage to be used for future research 
6. In good general health, without clinically significant medical history, and has satisfactorily completed screening  
7. Physical examination and labo ratory results without clinically significant findings within 
the 28 days prior to randomization  
Laboratory Criteria within 28 days prior to randomization:  
8. Hemoglobin within institutional normal range or accompanied by Principal Investigator (PI) or design ee approval  
9. White blood cell ( WBC ) differential either within institutional normal range or 
accompanied by PI or designee approval  
10. Total lymphocyte count: ≥800 cells/mm3 
11. Platelets : 125,000-500,000/mm3 
12. Alanine aminotransferase (ALT) : ≤ 1.25 x upper limit of  normal range 
13. Serum creatinine : ≤1.1 x upper limit of normal  
14. Negative for HIV infection by an FDA -approved method of detection  
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 17 of 66 
 
 Criteria  applicable to women of childbearing potential  
15. Negative beta-human chorionic gonadotropin ( β-HCG) pregnancy test (urine or serum) 
on day of randomization before receiving the study product  
16. Agrees to use an effective method of birth control, if sexually active, from at least 21 
days prior to  randomization through the last study visit.  
4.1.2 Exclusion Criteria  
A volunteer will be excluded if one or more of the following conditions apply: 
Female- Specific Criteria  
1. Breast -feeding or planning to become pregnant while participating in the study  
Volunteer has received any of the following: 
2. More than 10 days of systemic immunosuppressive medications or cytotoxic medications 
within the 4  weeks prior to randomization or any within the 14 days prior to 
randomization 
3. Blood products within 16 weeks prior to randomization  
4. Immunoglobulin within 8 weeks prior to randomization  
5. Prior vaccinations with an investigational alphavirus vaccine 
6. Investigational research agents wit hin 4 weeks prior to randomization or planning to 
receive investigational products while on study 
7. Live attenuated vaccines within 4 weeks prior to randomization  
8. Inactivated  vaccines within 2 week s prior initial study vaccine administration unless 
approved by the PI  
9. Current anti-TB prophylaxis or therapy 
Subject has a history of any of the following clinically significant conditions: 
10. A history of confirmed or suspected viral encephalitis infection  
11. Serious reactions to vaccines that preclude receipt of stud y vaccinations as determined by 
the investigator  
12. Hereditary  angioedema, acquired angioedema,  or idiopathic forms of angioedema 
13. Asthma  that is not well controlled  
14. Diabetes mellitus (type I or type II) with the exception  of gestational diabetes  
15. Thyroid disea se that is not well controlled  
16. Hypertension that is not well controlled  
17. Evidence of autoimmune disease or immunodeficiency 
18. Idiopathic urticaria within the last year  
19. Malignancy that is active or history of malignancy that is likely to recur  during the study 
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 18 of 66 
 
 20. Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or platelet 
disorder requiring special precautions) or significant bruising or bleeding difficulties with IM product administration  or blood draws 
21. Seizure disorder other than: 1) febrile seizures, 2) seizures secondary to alcohol withdrawal more than  3 years ago, or 3) seizures or treatment  for a seizure disorder 
within the last 3 years  
22. Asplenia, functional asplenia or any condition resulting in absence or removal of the spleen  
23. Psychiatric condition that precludes compliance with the protocol; past or present psychoses; or within 5 years prior to randomization , a history of suicide plan or attempt 
24. Any other chronic or clinically significant medical , psychiatric or social  condition that, in 
the judgement of the investigator is a contraindication to protocol participation or impairs a subject’s ability to give informed consent.     
4.2   Clinical Procedures And Evaluations  
Evaluation of this investigational vaccine will include l aboratory tests , medical history, physical 
examination  by clinicians and subject self -assessment .  The schedule of study visits is shown in 
the Schedule of Evaluations in Appendix III.   
4.2.1 Pre-screening  
Subjects will be recruited through Institutional Review Board (IRB) approved advertising.  To 
identify potential study subjects, study staff may discuss the VRC 313 clinical trial with those who express interest.  Study staff may use an  interview questionnaire to obtain self -reported 
medical history in order to determine if the  subject may be eligible based on protocol inclusion 
and exclusion criteria.   Potential subjects who appear to be eligible may continue to screen for 
this study.  No study- specific in terventions may be done during pre- screening.  
4.2.2 Screening  
Screening for this study will be gin completed after the subject sign s an informed consent form 
(ICF).  The screening process may occur over one visit or multiple visits in order for the site to 
fully assess each subject’s eligibility to participate in this study.   Screening evaluations must all  
be completed within the 28-day screening window.  The ICF may be signed more than 28 days 
before study randomization and does not need to be re-signed if outside of this window, unless required by the site’s IRB or an updated form becomes available. 
Assessment of Understanding : The Assessment of Understanding (AoU) is a tool to help study 
staff confirm the subject’s understanding of the consent information.  The AoU must be 
completed  at least once before the subject signs the ICF.  Incorrect answers on the AoU must be 
reviewed with the subject. Study clinicians must review the ICF with each potential subject.  Before screening procedures 
can be performed, informed consent must be obtained, and the form must be signed, dated  and 
timed  by the subject  as well as signed and dated by the consenter  and a witness .  Any member of 
the research/clinical team can be a witness, but a consenter and a witness should not be the same 
person at the same time.   
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 19 of 66 
 
 The template of the ICF is  provided in Appendix I. The site must use the template to develop 
site-specif ic forms as needed, adding relevant information as required by the site institutional 
policies . 
During Screening : 
• Medical History and Physical Examination : Study clinicians must obtain a medical 
history and perform a physical examination including collection of vital signs, height 
and weight within 28 days before randomization. 
• Injection Site Assessment : Clinicians should assess potential injection sites in the 
deltoid muscle.  Clinicians should avoid administering an injection in an area that has an injury , local skin problem or significant tattoo that interferes with evaluation of the 
injection site after product administration.  
• Pregnancy Prevention Counseling and Pregnancy Testing : Study clinicians must 
complete pregnancy prevention counseling on female subjects of childbearing potential to evaluate if subjects are able to meet the birth control eligibility criteria.   Pregnancy 
test results must also be confirmed as negative for these subjects during screening.   
• HIV Prevention Counseling : During screening, HIV counseling must be completed on 
all subjects being tested for HIV to ensure the subject is aware of how to reduce risk of and avoid HIV infection.  Every attempt must be made to provide the HIV test results to the subjects.  
• Blood Sample Collection : 
− Samples for clinical evaluation of eligibility criteria must be c ollected  no more 
than 28 days before randomization. Tests may be repeated as needed based on clinical judgment to confirm eligibility or if there is a suspected change in health status.  
− Samples for research must be collected during screening  per Schedule of 
Evaluations (Appendix III).  However, research samples obtained more than 28 days before randomization do not need to be repeated. Some samples collected during screening may be used for as say validation and site proficiency testing.  
• Eligibility Review : Based on results from the physical examination, medical history 
evaluation, blood tests and any additional health assessments performed during screening, the study clinicians will determine if subjects qualify to be randomized and receive the study product, and confirm this by documenting on the applicable data collection forms and in the database.  For subjects who are not eligible, the reason(s)  for 
ineligibility  must be recorded. 
4.2.3 Enrollment  
All subjects who sign the ICF following completion of the informed consent discussion must be 
enrolled into  the screening segment of the database.   
4.2.4 Randomization 
Visit 02 (Day 0) is defined as the day of study randomization and first product administration. 
If a subject presents with fever or other signs of illness during the first product administration 
visit, do not randomize the subject and do not order or administer study product.  Instead, review 
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 20 of 66 
 
 the subject’s medical hist ory and conduct a targeted physical examination, as needed.  If there 
are no exclusionary findings or significant illness and the subject becomes well, the 
randomization visit may be rescheduled within the 28-day allowable screening period.  If Visit 
02 cannot be rescheduled within the 28-day window, re- test and re- evaluate all required 
screening parameters in order to ensure eligibility prior to rescheduling the subject for randomization. 
Before Randomization :  
• Pregnancy Prevention Counseling and Pregnancy  Testing : Pregnancy prevention 
counseling must be conducted, and pregnancy test results must be confirmed negative 
for females of childbearing potential.  
• Medical History Review and Targeted Physical Examination : Review health status 
and current medication s including recent vaccinations, measure vital signs, and re- assess 
potential injection sites.  
• Eligibility Confirmation : Eligibility criteria must be reviewed prior to randomization in 
the study database.  
Randomization : Subjects are electronically randomized upon entry in the database to the open 
dose group to receive vaccine alone or vaccine plus alum, based on a randomization plan prepared in advance by the Protocol Statistician.   Randomization and product administration 
must both occur on the same day at Visit 02 (Day 0).  
Baseline Values for Future Health Assessments : Visit 02 evaluations and medical history that 
were obtained prior to the first product administration will be used as the baseline for all future 
safety assessments.  If a blood test was not performed at Visit 02 or if results were not obtained due to an error, the values that were obtained during screening evaluations may be used as the baseline for all future safety assessments.  
4.2.5 Study Schedule  
The Schedule of Evaluations in Appendix III provides details on the study schedule and the 
permitted visit windows.  A clinician should discuss the target dates and timing of the study 
vaccination(s) and sample collections before completing a randomization to help ensure that the subject can comply with the projected schedule. 
The schedule of study visits, permitted windows for completing the visits, and evaluations 
performed at each visit are shown in Appendix III.  After randomization, deviations from the visit windows in completing study visits an d study product administrations are discouraged and 
will be recorded as protocol deviations, but are permitted at the discretion of the IND Sponsor. 
Important Information about Shifting Study Visits  
Study visits are scheduled a specific number of days apart in order to obtain blood samples for 
safety and research data at critical time points after each product administration.  Note that these 
days are calendar days and not working business days.  Therefore, the “Day of Study” is important to consider wh en scheduling or rescheduling a subject visit.  All study visits are 
scheduled based on the date of the most recent product administration.  Below is further explanation on scheduling. 
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 21 of 66 
 
 Visit 02 (Day 0) = first product administration visit.  Study Visits 02A through 05 must be 
scheduled based on the date of the first product administration.  
Visit 05 = second product administration visit.  Study Visits 05A through 09 must be scheduled 
based on the date of Visit 05.  For example, if Visit 05 occurs +/-7 calendar days outside of the 
visit window, then Visits 03A through 09 must also be moved ahead +/-7 calendar days.  If the 
second product administration does not occur, then schedule all follow-up visits based on the date of the first product administration.  
4.2.6 Product Administration  
Before Ordering Study Product : Pregnancy prevention counseling must be conducted, and 
pregnancy test results must be confirmed negative for females of childbearing potential.  
Subjects must be clinically evaluated with a medical history review and injection site assessment. Blood samples must be collected after randomization but prior to product administration per Appendix III.  
Ordering Study Products : The s ite must follow standard operating procedures to order study 
product from the Pharmacy. 
Product Administration Procedures : It is recommended, but not required, that the first 
vaccination be administered into the non-dominant arm.  It is preferred, but not required, to 
alternate arms for  a subsequent product administration, if applicable.  When choosing an arm for 
the product administration, clinicians should consider whether there is an arm injury, local skin 
problem or significant tattoo that precludes the adminis tration of the study product or will 
interfere with evaluating the arm after product administration .  All product administrations will 
be administered IM into upper arm deltoid muscle by needle and syringe.   
For groups receiving adjuvant, the adjuvant wil l be added  by the site pharmacist  prior to delivery 
to the clinic for administration.  
Prior to each product administration, the syringe MUST be inverted 5 times .  “Inversion ” of 
a prepared syringe is defined as a gentle, complete 180 degree rotation, do not “ shake ” the 
syringe.  
For the Second Product Administration: If a subject presents with fever or other signs of 
significant illness on the day of the product administration visit, do not order or administer study 
product.  Unscheduled visits may be used to evaluate the subject’s condition and the administration visit should be rescheduled within the allowable visit window. 
If a subject is undergoing evaluation and/or treatment for a medical condition at the time of the 
second scheduled administration visit, then vaccinations should be delayed until the condition has resolved or is considered stable.  Contact the IND Sponsor for questions about resuming or discontinuing vaccinations as  needed .  
To schedule a product administration visit outside of the allowable visit window, the site must  document PI approval. 
Post Product Administration Procedures : Following product administration , all subject s will 
be observed for a minimum of 30 minutes.  Vital signs (temperature, blood pressure, pulse , and 
respiratory rate) will be collected  at least  30 minutes after product administration, prior to subject 
departure from the clinic.  The injection site will be inspected for evidence of local reaction.  
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 22 of 66 
 
 In keeping with good medical practice, acute medical care will be provided to subjects for any 
immediate allergic reactions or other injury resulting from participation in this research study.  
4.2.7 Safety Evaluations and Follow- up after Product Administration 
Prior to the end of the visit a fter each product administration, s ubjects will be given a “Diary 
Card” to use as a memory aid, on which to record temperature and symptoms daily for 7 days.  Subjects will also record the day’s highest measured temperature and measurement of the largest  
diameter of rednes s and swelling at injection site.   
Subjects will be trained and encouraged to use a secure electronic database but have the option to 
complete a paper diary card.  When the parameters are recorded directly by the subject  
electronically , the subject’s electronic record will be the source for these data.  The paper diary 
card may be used as a source document.  When neither a paper  nor electronic diary card is 
available, the study clinician will note the source of reactogenicity information recorded in the study database.    
The solicited signs and symptoms on the diary card will include  the following parameters: 
pain/tenderness at injection site , erythema (redness)  at injection site , induration (swelling) at 
injection site , temperature, unusually tired/feeling  unwell, muscles aches (other than at injection 
site), arthralgia (joint pain) , headache, chills  and nausea.   
Follow-up on subject well-being will be performed by telephone 2 days post each product 
administration.  Subject diaries are reviewed for accurac y and completeness at follow-up in -
person visits .  Clinicians will follow and collect resolution information for any reactogenicity 
symptoms that are not resolved within 7 days.  
Events following any study product administration  that may r equire clinical evaluation include 
rash, urticaria, arthralgia, fev er of 38.5˚C (Grade 2) or higher lasting greater than 24 hours, or 
significant impairment in the activities of daily living.  Additionally, other clinical concerns may 
prompt a study visit based on the judgment of a study clinician.  If a skin lesion or ot her 
unexpected reaction at the injection site occurs in this study, we may ask the subject to allow us to take a photograph.  If the subject agrees, he/she will be asked to sign a site -specific 
photography informed consent form.  
Any subject who receives at least one vaccination  is expected to continue with safety follow-up 
through study Week 36. 
4.2.8 Blood Sample Collection  
At intervals throughout the study, blood will be drawn for safety evaluations  and immunologic 
assays.   Blood will be drawn from the arm veins of subjects by standard phlebotomy procedures.  
As per NIH Clinical Center (CC) guidelines, total blood volume drawn from adult subjects (who 
weigh at least 50 kg) will not exceed 550 mL in any 8-week period.  The site must also follow institutional policy for blood collection.  
4.2.9 Concomitant Medications  
Only routine prescription medications  at the time of randomization are recorded in the study 
database.  Subsequently, c oncomitant medications are only updated or recorded in the database if 
there is an occurrence of an AE that requires expedited reporting or if the subject develops a new 
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 23 of 66 
 
 chronic condition th at requir es ongoing medical management .  Receipt of a FDA -approved 
vaccine at any time during the study will be recorded in the database (clinicians should work 
with subjects regarding the timing of licensed vaccines relative to product administration ).  
Otherwise, the concomitant medication changes throughout the study will be recorded in the subject’s chart as needed for general medical records, but will not be recorded in the database.  
4.3    Dose Escalation  
There will be two dose escalation  review s in this  study.  The Protocol Safety Review Team 
(PSRT, Section 8.8.1) will conduct an interim safety review of all available data at the time of 
the review .  The PSRT must assess the data as showing no significant safety concerns before 
escalation to the next dose. 
Randomization will begin in Group 1 (6 mcg WEVEE) and Group 2 (6 mcg WEVEE + alum ).  
No more than one subject will be randomized and vaccinated per day  for the first 3 subjects at 
each dose.   
1) The first interim safety review for dose escalation will be conducted when safety data for 
the first 3 subjects to receive 6 mcg WEVEE become available for the visit two weeks 
after vaccination  (Visit 03 /Day 14) .  Subject  randomization s and vaccination s in Group 1 
and Group 2 may continue during the interim safety review ; however, randomizations 
should be completed prior to beginning Group 3 and 4 randomizations. 
If the  6 mcg dose of WEVEE is assessed as not showing safety concerns by the PSRT, 
randomization can begin for Group 3 and Group 4.  
Randomization will proceed in Group 3 (30 mcg WEVEE) and Group 4 (30 mcg WEVEE + 
alum ).  
2) The second interim safety review for dose escalation will be conducted when safety data  
for the first 3 subjects to receive 30 mcg WEVEE  become available for the visit two 
weeks after vaccination  (Visit 03 /Day 14).  Subject randomizations and vaccinations in 
Group 3 and Group 4 may continue during the interim safety review ; however, 
randomizations should be completed prior to beginning Group 5 and 6 randomizations. If the 30 mcg dose is assessed as safe, randomization can begin for Group 5 (60 mcg 
WEVEE) and Group 6 (60 mcg WEVEE + alum ). 
If an initial study vaccination is not completed or there are discontinuations from the study 
before there are sufficient data to conduct the dose escalation review, then extra subjects may be randomized at the same dose level  in order to have the requisite data on at least 3 subjects in 
these groups.  The IRB will be provided with documentation of the safety review process and notification of the dose escalation.  Consultation with the IRB and FDA, if needed, as per study pause criteria ( Section 4.4
) will occur if indicated by the review.   One outcome of a dose 
escalation rev iew may be to  recommend evaluation of additional subjects at the current dose 
level and reassess for safety before proceeding to a higher dose level.  
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 24 of 66 
 
 4.4    Pausing and Resuming the Study  
4.4.1 Criteria for Pausing the Study  
The Protocol Chairs, in consultation with site PI , will closely monitor and analyze study data as 
they become available and will make determinations regarding the presence and severity of AEs.  
The administration of  study products and  new enrollments will be paused and the IND Sponsor 
will be promptly notified according to the following criteria:  
• One (or more) subject experiences a SAE  assessed as related to the study product 
(with or without adjuvant). 
• Two  (or more) subjects experience the same Grade 3 or higher AE  assessed as 
related to the study product (with or without adjuvant). Pause is not required for s elf-
limited  solicited reactogenicity (generally defined as resolved within 2 days of onset) 
following any study vaccination.  
• Three (or more) subjects experience the same or similar Grade 3 solicited AE  (other 
than injection site redness or swelling) lasting > 24 hours.  
4.4.2 Plan for Review of Pauses and Resuming the Study  
Study randomizations and  product administrations would resume only if review of the events 
that caused the pause resulted in a recommendation to permit further randomizations and product administration s.  The review to make this decision will occur as follows:  
• The IND Sponsor, with participation by the Protocol Chairs an d site PI, will conduct the 
review and make the decision to resume or close the study for any SAEs  or AEs  that meet 
the criteria for pausing the study.  
o As part of the pause review, the reviewers will also advise on whether the study needs 
to be paused again for any subsequent AEs of the same type.  The FDA and the IRB 
will be notified of SAE and Grade 3 or higher pause reviews and of the IND Sponsor’s decisions.  
4.4.3 Dose -Limiting Toxicity  
Dose -limiting toxicity is defined in this protocol as an AE  that prevents a dose escalation of the 
study vaccine or prevents continuation of product administrations at a gi ven dose level.  If the  
study is paused as per criteria in Section 4.4.1
 and a decision is made to not resume the study 
vaccinations at the current dose, then the safety review will include a decision as to whether or not to continue accrual at a lower vaccine dose that was evaluated to be safe in order to achieve the target study accrual of  30 subjects.  
4.5    Discontinuation of Product Administrations or Study  Participation    
Decisions to discontinue giving the second product administration  or to discontinue protocol 
participation for a subject will be made by  the site PI or designee.  
4.5.1 Discontinuation of Product Administrations  
A subject may be discontinued from receiving study product for the following reasons: 
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 25 of 66 
 
 1. Pregnancy;  
2. Grade 3 adverse event assessed as related to the study product (with the except ion that 
self-limited Grade 3 solicited reactogenicity does not require discontinuation of study 
injections ); 
3. Grade 4 adverse event assessed as related to the study product;  
4. Immediate hypersensitivity reaction associated with the study product; 
5. Intercurre nt illness that is not expected to resolve prior to the next scheduled study 
product administration;  
6. Treatment with systemic glucocorticoids (e.g., prednisone or other glucocorticoid) or 
other immunomodulators (other than nonsteroidal anti- inflammatory dr ugs [NSAIDs]), 
with the exception that study product administration may continue per site PI discretion if 
the next one occurs at least 2 weeks following completion of glucocorticoid treatment; 
7. The IND Sponsor and/or PI assess that it is not in the best interest of the subject to continue receiving study product. 
Subjects  who receive at least one study product will continue follow-up according to the 
Schedule of Evaluations, except that the research sample collections will be discontinued for pregnant women or others in which it is contraindicated. 
4.5.2 Discontinuation from Protocol Participation  
A subject may be discontinued from protocol participation for the following reasons: 
1. Subject voluntarily withdraws 
2. Subject develops a medical condition that is a contraindication to continuing study 
participation  
3. The IND Sponsor or regulatory authorities stop the protocol 
4. The IND Sponsor and/or PI assess that it is not in the best interest of the subject to continue participation or that the subject’s compliance with the study is not sufficient  
5. Co-enrollment into a study in which other investigational research agents will be 
administered before the subject has completed the follow- up after the last WEVEE 
vaccine administration; 
5 SAFETY AND ADVERSE E VENTS  
5.1    Adverse Events  
An adverse event (AE) is any untoward or unfavorable medical occurrence in a human subject, including any abnormal sign (e.g., abnormal physical exam or laboratory finding), symptom, or 
disease temporally associated with the use of study  treatment, whether or not considered related 
to the study product.   
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 26 of 66 
 
 Each AE  will be graded according to the T able for G rading S everity of Adverse Events  (see 
Appendix IV ).  The following guidelines will be used  to determine when or not an AE should be 
recorded in the study database:  
• From the time that subject signs the ICF, only AE that meet the definition of a SAE as 
described in Section 5.2 that occur within 24 hours of a screening visit will be reported.  
• Solicited AE s (i.e, reactogenicity parameters) will be recorded in the study database per 
diary card entries  for 7 days after each product administration  and is not recorded with 
attribution assessments.  Clinicians will follow and collect resolution information for any reactogenicity symptoms that are not resolved within 7 days.  
• Unsolicited AEs and attribution assessments will be recorded in the study database from 
receipt of the first product administration  through the visit scheduled for 4 weeks after 
each product administration .  At other time periods between product administra tions and 
when greater than 4 weeks after the last study product administration , only SAEs (as 
detailed in Section 5.2
) and new chronic medical conditions that require ongoing 
medical management  are recorded throu gh the last study visit.  
5.2    Serious Adverse Events   
The term “serious adverse event” (SAE) as defined in US 21 Code of Federal Regulations  (CFR ) 312.32 as follows: “ an adverse event or suspected adverse reaction is considered “serious” 
if, in the view of either the investigator or sponsor, it results in any of the following outcomes: Death, a life -threatening adverse event, inpatient hospitalization or prolongation of e xisting 
hospitalization, a persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions, or a congenital anomaly/birth defect. Important medical events 
that may not result in death, be life -threatening, or require hospitalization may be considered 
serious when, based upon appropriate medical judgment, they may jeopardize the patient or 
subject and may require medical or surgical intervention to prevent one of the outcomes listed in 
this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse.”  
“Life threatening” refers to an AE  that at occurrence, represented an immediate risk of death  to 
the subject . An event that  hypothetically may cause death if  it occurs  in a more severe form  is 
not considered life- threatening. Similarly, a hospital admission fo r an elective procedure is not 
considered a SAE . 
5.3    Adverse Event Reporting to the IND Sponsor  
All AEs  that meet  the definition of a SAE  must be reported from receipt of the first  product 
administration  through the last study visit by the study site and submitted on an expedited basis 
to the IND Sponsor, VRC, according to s ponsor guidelines as follows:  
• results in death  
• is life threatening  
• results in persistent or significant disability/incapacity  
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 27 of 66 
 
 • requires unplanned inpatient hospitalization or prolongation of existing 
hospitalization  
• is a congenital anomaly/birth defect in the offspring of a study subject 
• is an important medical event that may jeopardize the subject or may require intervention to prevent one of the other outcomes listed above. 
 
In addition, any event, regardless of severity, which in the judgment of an investigator represents a SAE , may be reported on an expedited basis. 
The site investigator will communicate an initial SAE report within 1 business day of site 
awareness of occurrence to the IND Sponsor by data entry in the database.  Any SAE entered 
into the study database will generate an automatic email notification to the IND Sp onsor.  The 
site must remove personal identifying information about the subject from SAE case reports before submission to the IND Sponsor. 
A full written report by  the site  investigator should be submitted to the IND Sponsor within 3 
working days and as soon as possible in case of death .  In order for the IND Sponsor to comply 
with regulations mandating sponsor notification of specified SAEs to the FDA within 7 or 15 
calendar days, the investigator must submit additional information as soon as it is available.   
5.3.1    IND Sponsor Reporting to the FDA  
It is the responsibility of the IND Sponsor to make the determination of which SAEs are “serious 
and unexpected suspected adverse reactions” (SUSARs) as defined in 21 CFR 312.32. 
• Suspected adverse reaction  means any AE  for which there is a reasonable possibility 
that the drug caused the AE. 
• Unexpected adverse e vent means an AE that is not listed in the IB or is not listed at 
the specificity or severity that has been observed.   
All SUSARs, as determined by the IND Sponsor, will be reported to the FDA as IND Safety 
Reports.  All  IND Safety Reports will be provided to the site PI by the IND Sponsor or delegat ed 
representative. 
The IND Sponsor will submit an IND Annual Report of the progress of the investigation to the 
FDA as defined in 21 CFR 312.33. 
5.4    Reporting to the Institutional Review Board  
The site should following the reporting procedures and requireme nts established by the site  IRB.  
The definitions below are provided as guidance and should not supersede the site ’s IRB policies.   
The FDA “Guidance for Clinical Investigators, Sponsors, and IRBs: Adverse Event Reporting to IRBs – Improving Human Subject Protection” is recommended for use and can be found at the following location: https://www.fda.gov/downloads/regulatoryinformation/guidances/ucm126572.pdf
. 
5.4.1 Unanticipated Problem s 
An unanticipated problem (UP) is defined as any incident, experience, or outcome that meets all three of the following criteria: 
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 28 of 66 
 
 • unexpected in nature, severity, or frequency in relation to the research risks that are 
described in the protocol, informed consent , IB, other study documents or in 
consideration of the characteristics of the subject population being studied; and  
• related to participation in the research; and  
• suggests that the research places subjects or others at a greater r isk of harm (including 
physical, psychological, economic, or social harm) than was previously known or recognized.  
Serious UP: An UP that meets the definition of a SAE or compromises the safety, welfare or rights of subjects or others. 
An UP that is not an AE ( UPnonAE) is an unanticipated problem that does not fit the definition 
of an AE , but which may, in the opinion of the investigator, involve risk to the subject, affect 
others in the research study, or significantly impact the integrity of research data.  Such events 
may also  be considered a UP.  For example, we will report occurrences of breaches of 
confidentiality, accidental destruction of study records, or unaccounted- for study drug.  
5.4.2 Protocol Deviations 
A protocol deviation is defined as any change, divergence, or departure from the IRB -approved 
study procedures in a research protocol.  Protocol deviations are designated as serious or non-serious and further characterized as : 
• Those that occur because a member of the research team deviates from the pro tocol. 
• Those that are identified before they occur, but cannot be prevented. 
• Those that are discovered after they occur.  
Serious Protocol Deviation: A deviation that meets the definition of a SAE  or compromises the 
safety, integrity of the data, welfare or rights of subjects or others. 
5.4.3 Non-Compliance  
Non-compliance is the failure to comply with applicable NIH Human Research Protections 
Program (HRPP) policies, IRB requirements, or regulatory requirements for the protection of 
human subjects.  Non -complian ce is further characterized as serious, continuing or minor. 
“Serious non-compliance” is defined as non- compliance that  
• Increases risks, or causes harm, to participants  
• Decreases potential benefits to participants  
• Compromises the integrity of the NIH-HRPP  
• Invalidates the study data  
“Continuing non-compliance” is non- compliance that is recurring.  
“Minor non-compliance” is non-compliance that is neither serious nor continuing. 
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 29 of 66 
 
 5.4.4 Expedited and Annual Reporting to the site  IRB  
Expedited  and annual report ing to the site  IRB will be completed  by the site per the institutional 
requirements.  
6 STATISTICAL CONSIDERATIONS  
6.1    Overview  
This study is a Phase I, randomized, open-label, dose- escalation study  to examine  the dose, 
safety , tolerability,  and immunogenicit y of  VRC -WEVVLP073-00- VP (WEVEE) alone or with 
alum adjuvant at Day 0 and Week 8 .  The primary objective relates to safety and tolerability; the 
secondary and exploratory objectives relate to the immunogenicity of the study product.   
6.2    Endpoints  
6.2.1 Primary  Endpoints: Safety  
Assessment of product safety will include clinical observation and monitoring of hematological 
and chemical parameters.  Reactogenicity will be closely monitored for 7 days after each product administration  and safety evaluated by clinical visits through the study duration of 36 weeks.  
The following parameters will be assessed  for all study groups : 
• Local reactogenicity signs and symptoms for 7 days after each injection  
• Systemic reactogenicity signs and symptoms for 7 days after each injection  
• Laboratory measures of safety   
• AEs  
• SAEs  
• New chronic medical conditions    
6.2.2 Secondary Endpoints: Immunogenicity  
The immunogenicity endpoints are antigen -specific antibody responses as evaluated by  virus-
specific neutralization assays.  The primary time point for immunoge nicity evaluation is 4 weeks 
after the second vaccination. 
6.2.3 Exploratory Endpoints: Immunogenicity 
Exploratory immunogenicity endpoints are measured by virus- specific  neutralization assay s, 
ELISA,  and other research tests as described in Section 1.6 
6.3    Sample Size  and Accrual  
Recruitment will target 30  healthy adult participants divided equally among 6 groups. 
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 30 of 66 
 
 6.3.1 Power Calculations for Safety 
The goal of the safety evaluation for this study is to identify safety concerns associated with 
product administration of the investigational vaccine.  Primary sample size calculations for safety are expressed in terms of the ability to detect serious adverse experiences.  
The ability of the study to identify SAEs will be expressed in terms of the probability of observing a certain number of SAEs .  Useful values are the minimum true rate such that the 
probability of observing at least one event is at least 90%, and the maximum true rate such that 
the probability of not observing any event is at least 90%.  Within each group (n=5), there is over 
90% chance to observe at least 1 SAE if the true rate is at least 0. 37 and over 90% chance to 
observe no SAE if the true rate is no more than 0. 02. 
Probabilities of observing 0 or more than 1 SAE  within each group are presented in Table 2 for a 
range of possible true event rates.  These calculations provide a more complete picture of the sensitivity of this study design to identify potential safety problems with the vaccine.  
Table 3 gives the u pper and lower bounds for 95% exact binomial confidence intervals of the 
true SAE rate at all possible numbers of events within each group (n=5).  If none of the 5 vaccines experience serious adverse events, the 95% exact 2 -sided upper confidence bound for 
the SAE rate is 0. 522. 
Table 2: Probability of Events for Different Safety and Immunogenicity Scenarios 
within a Group (n=5)  
True Event rate  Pr (observing 0 event)  Pr (observing more than 1 event)  
0.005  0.975 0 
0.01 0.951 0.001 
0.02 0.904 0.004 
0.035  0.837 0.011 
0.05 0.774 0.023 
0.1 0.59 0.081 
0.15 0.444 0.165 
0.2 0.328 0.263 
0.3 0.168 0.472 
Table 3: 95% Confidence Intervals for the True Rate At  All Possible Observed Rates 
within a Group (n=5)  
 95% Confidence Interval  
Observed Rate  Lower Bound  Upper Bound  
0/5 0 0.522 
1/5 0.005 0.716 
2/5 0.053 0.853 
3/5 0.147 0.947 
4/5 0.284 0.995 
5/5 0.478 1 
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 31 of 66 
 
 6.3.2 Sample Size Calculations for Immunogenicity  
Table 2 gives the probabilities of observing 0 or at least 2 responses over a range of underlying 
response rates.  For example, if the true response rate at a particular time point is 0.20, then there is a probability of 0.672 to observe at least one response and a probability of 0.263 to observe at least 2 responses among the 5 vaccinees in a group. 
Table 3 is applicable to the immunogenic response rates, and gives the exact 95% confidence 
interval of the true response rate over possible number of responses out of the 5 subjects.  For 
example, if we observe 2 responses among the 5 vaccinees, the 95% exact binomial confidence 
interval of the true response rate will range from 0. 053 to 0.853.  
6.3.3 Power for Comparison  
For groupwise  difference in immunogenicity, a simple comparison on the positive response rate 
will be used.  Table 4 gives the power of Fisher exact test to compare any two schedules over a 
range of possible response rates  and indicates that this study is not powered for group 
comparison.  
Table 4: Power  (%) to Detect Difference in Response Rates between Two groups by 
Fisher’s Exact Test, Each Group of Size n=5  
 Arm 1 Rate (n=5)  Arm 2 Rate (n=5)   0.2 0.3 0.4 0.5 
0.1 1 1 5 12 
0.2 1 1 3 7 
0.5 7 4 2 2 
0.6 14 8 4 2 
6.4    Statistical Analysis  
Since randomization is concurrent with receiving the first study vaccination, the expectation is that all randomized participants will receive at least one vaccination and therefore will provide 
some safety data.  All statistical analyses will be performed using Statistical Analysis System 
(SAS) or statistical software  R.  No formal multiple comparison adjustments will be employed 
for safety endpoints or immunogenicity endpoints.  
6.4.1 Analysis Variables 
The analysis variables consist of baseline variables, safety variables, and i mmunogenicity 
variables for primary and secondary objective analyses.  
6.4.2 Baseline Comparability  
Baseline characteristics including demographics and laboratory measurements will be 
summarized using descriptive statistics.  
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 32 of 66 
 
 6.4.3 Safety Analysis 
Reactogenicities  
The number and percentage of participants experiencing each type of reactogenicity sign or 
symptom will be tabulated by severity.  For a given sign or symptom, each participant’s reactogenicity will be counted once under the maximum severity for all assess ments.  
Adverse Experiences  
Adverse experiences are coded into Medical Dictionary for Regulatory Activities (MedDRA) 
preferred terms.  The number and percentages of participants experiencing each specific adverse 
event will be tabulated by severity and relationship to treatment.  For the calculations in these tables, each participant’s adverse experience will be counted once under the maximum severity or strongest recorded causal relationship to treatment. 
A complete listing of adverse experiences for each p articipant will provide details including 
severity, relationship to treatment, onset, duration and outcome. 
Local laboratory values 
Boxplots of local laboratory values will be generated for baseline values and for values measured 
during the course of the s tudy.   Each boxplot will show the 1st quartile, the median, and the 3
rd 
quartile.  Outliers, or values outside the boxplot, will also be plotted.  If appropriate, horizontal lines representing boundaries for abnormal values will be plotted. 
6.4.4 Immunogenicity Analysis 
The statistical analysis for immunogenicity will employ the intent- to-treat principle, i.e., all data 
from randomized participants will be used.  In the final analysis of immunogenicity, if there are 
cases of a subject receiving a schedule different from the assignment, then an as- treated analysis 
will be performed. 
If assay data are qualitative (i.e., positive or negative) then analyses will be performed by 
tabulating the frequency of positive response for each assay at each time point that an ass essment 
is performed.  Binomial response rates will be presented with their corresponding exact 95% 
confidence interval estimates.   Fisher’s exact tests will be used to compare the two vaccine 
groups to each other.  Missing responses will be assumed to be missing at random, i.e., 
conditional on the observed data the missingness is independent of the unobserved responses.  Graphical descriptions of the longitudinal immune responses will also be given. 
Some immunologic assays have underlying continuous or count-type readout that is often 
dichotomized into responder/nonresponder categories.  For these assays, graphical and tabular 
summaries of the underlying distributions will be made.  These summaries may be performed on 
transformed data ( e.g., log transformat ion) to better satisfy assumptions of symmetry and 
homoscedasticity.  
6.4.5 Missing Data 
Missing responses will be assumed to be missing completely at random.   Analyses will include 
all samples available at each study time  point. 
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 33 of 66 
 
 6.4.6 Interim Analyses  of Immunogenicity 
An interim analysis of immuno genicity data may be performed  when half of vaccinated  
participants reach the primary endpoint for immunogenicity evaluation at 4 weeks after the last 
product administration.  Reports will be provided to the Protocol Chairs, and other key VRC 
investigators solely for the purpose of informing future trial- related decisions in a timely manner.  
Results will remain confidential and should in no way influence the conduct of the VRC 313 trial 
in terms of early term ination or later safety or immunogenicity endpoint assessments. 
6.5    Randomization of Intervention Assignment s  
Randomizations will be done online using an electronic randomization system.  The 
randomization code will be prepared  by the Protocol Statistician  and included in the 
randomization module for the trial.  The randomization code will link to the intervention 
assignment.  The electronic data system will assign each subject a randomization code after eligibility has been confirmed in the system.  
At the beginning of the study, subjects will be randomized 1:1 to Groups 1 and 2. If the criteria for the first dose escalation are met  and procedures for the interim safety review are completed , 
subjects can  be randomized 1:1 to  Groups 3 and 4.  For practical purposes, accrual  and 
randomization to Groups 1 and 2 should be completed as per study plan before accrual  to Groups 
3 and 4 begins. 
If the criteria for the second dose escalation are met  and procedures for the interim safety review 
are completed, subjects can  be randomized 1:1 to  Groups 5 and 6.  For practical purposes, 
accrual  and randomization to Groups 3 and 4 will be completed as per study plan before accrual  
to Groups 5 and 6 begins.  The subject and study clinicians will be informed on the subject’s group assignment upon 
completing randomization in the electronic data collection  system.  
To decrease the potential for subject dropouts during the period between randomization and product administration will occur on Day 0 when  eligibility is  confirmed.  If subjects accrued to 
a study group do not complete the number of vaccinations and follow-up duration specified, then additional subjects may be accrued in that group.  
7 PHARMACY PREPARATION AND ADMINISTRATION 
PROCEDURES  
The study groups and s tudy vaccine dosing schedule are shown in the Vaccination Schema in 
Section 4 . Refer to the IB for further information about the investigational study products. 
7.1    Study Products   
This clinical trial includes one investigational vaccine , one  adjuvant, and one diluent as follows: 
• VRC -WEVVLP073-00- VP, 78 mcg/mL in formulation buffer filled to a volume of 
1.2 mL  in a 3 mL single  dose vial. 
• Aluminum Hydroxide Suspension ( alum ) as adjuvant at a concentration of 
approximately 5 mg/mL at a volume of 0.7 mL  in a 3 mL single dose vial.  
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 34 of 66 
 
 • VRC -PBSPLA043-00-VP, phosphate buffered saline (PBS), pH 7.2, as diluent filled 
to a volume of 1.2 mL in a 3 mL single  dose vial.  
All study products were manufactured  under c GMP by the VRC Pilot Plant and must meet lot 
release specifications prior to administration for use in the clinical study.  A ll subjects in this trial 
are scheduled to be vaccinated with a single lot of vaccine.  
When released for use in the clinical trial, the vials are shipped to  the study pharmacist using 
appropriate shipping arrangements according to Leidos Biomedical VCMP SOPs .  
7.2    Study Product Presentation, Stability, and Storage  
7.2.1 Labels  
At the time of study product delivery to the pharmacy, labels on study products, VRC-
WEVVL P073-00- VP and VRC -PBSPLA043-00-VP, will have specific product information 
(e.g., product description, VRC product number, lot number, fill volume, concentration, fill date, 
storage condition).  Labels will contain an Investigational Use Statement (“Limite d by Federal 
Law to Investigational Use”), and manufacturer information. 
7.2.2 Stability  
All study agents and diluent are placed on stability testing at the VRC  Pilot Plant. Stability 
studies are performed according to International Conference of Harmonisation ( ICH) guidelines. 
Vials are intended for single use only and thus do not contain a preservative.  7.2.3 Storage 
Study products will be shipped to the study pharmacy at the recommended temperature range 
using appropriate shipping arrangements according to Leidos B iomedical VCMP SOPs . 
VRC -WEVVLP073-00- VP: Vials of vaccine are stored until use at ≤  -60°C in a qualified, 
continuously monitored temperature-controlled freezer  (DO NOT STORE AT -45°C to -10°C). 
Vials, intended for single use only and should not be refrozen after thaw.  Vaccine vials are 
removed from the freezer and equilibrated to room temperature prior to product administration. 
VRC -GENMIX083 -AL-VP: Vials of alum are stored until use at 2°C to 8°C in a qualified, 
continuously temperature monitored refrigerator.  Do not freeze.  Vials of adjuvant are intended for single use only. 
VRC -PBSPLA043-00- VP: Vials of PBS are stored until use between -45°C to -10°C in a 
qualified, continuously temperat ure monitored, non- frost-free freezer.  Vials of diluent are 
intended for single use only and should not be refrozen  after thawing.  
7.2.4 Deviations in Temperatures  
Temperature excursions that are outside of the specified ranges  will be reported per pharmacy 
guidelines.  If deviations in storage temperature occur from the the normal allowance as 
described in the IB , the site pharmacist or designee must report the storage temperature 
excursion promptly to the PI and IND Sponsor and product must be quarantined in a separate area.   
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 35 of 66 
 
 The excursion must be evaluated and investigated and action must be taken to restore and 
maintain the desired temperature limits.   Pending the outcome of the investigation, the IND 
Sponsor will notify the pharmacist or designee if continued clinical use of the product is 
acceptable.  
7.3    Preparation  of S tudy Product  for Administration  
Refer to the IB for information on study products preparation and use.  Refer to the group 
assignment for the study subject to select the proper product type. 
The pharmacy will label the syringe before delivery to the clinic  with the subject identifier, the 
date, and the time allowance for administration.   The injection must be administered within 2 
hours after removing the vial from the freezer.  
VRC -WEVVLP073-00- VP is supplied in a 3 mL glass vial with 1.25 mL of vaccine at a 
concentration of 78 mcg/mL.  Vials contain a clear solution; some small white translucent 
particles may be visible.   Vials with visible particles may be used.   Vials are intended for single 
use only and thus do not contain a preservative.  
The following general instructions apply to preparing all vaccine doses (alone and with adjuvant ) 
for product administration : 
1. Preparation will be done by a Pharmacist in a clean preparation unit with limited access.  
2. Prepare all doses under sterile conditions. 
3. Thaw the vial(s) containing VRC-WEVVLP073- 00-VP at room temperature (15 -27ºC) ; 
acclimate vials of adjuvant to the same temperature.  
4. Keep the material at room temperature or refrigerated during the entire preparation period 
until product administration (no longer than 2 hours following removal of vial from the freezer ). 
5. Keep the prepared study product out of direct sunlight. 
6. All preparation instructions assume the exact dos e withdrawn will be administered; draw 
more if an overage is needed for study product accuracy.  
7. “Inversion ” of a prepared vial or syringe is defined as a gentle, complete 180 degree 
rotation of the container.  Therefo re, when instructed to “ invert ”, do not “ shake” the 
product or syringe. 
7.3.1 Preparation of VRC- WEVVLP073 -00-VP 
Preparation of Vaccine Alone  (6 mcg dose) 
1. Transfer 2.4 mL PBS diluent to a new container ( sterile polypropylene microcentrifuge 
tube or glass vial ). 
2. Add 0.2 mL WEVEE vaccine to the same container.  
3. Invert 5x to mix. 
4. Withdraw 1.0 mL into a syringe.  
5. Invert 5X to mix immediately prior to administration.  
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 36 of 66 
 
 Preparation of Vaccine Alone  (30 mcg dose) 
1. Transfer 0.8 mL PBS diluent to a new container (sterile polypropylene microcentrifuge 
tube of glass vial).  
2. Add 0.5 mL WEVEE vaccine to the same container.  
3. Invert 5x to mix. 
4. Withdraw 1.0 mL into a syringe.  
5. Invert 5X to mix immediately prior to administration.  
Preparation of Va ccine Alone  (60 mcg dose) 
1. Transfer 0.3 mL PBS diluent to a new container (sterile polypropylene microcentrifuge tube of glass vial).  
2. Add 1.0 mL WEVEE vaccine to the same container.  
3. Invert 5x to mix. 
4. Withdraw 1.0 mL into a syringe.  
5. Invert 5X to mix immediately prior to administration.  
7.3.2 Preparation of VRC- WEVVLP073 -00-VP plus Adjuvant  
Preparation of Vaccine with Adjuvant  (6 mcg  + alum ) 
1. Gently invert vial of aluminum hydroxide 5x to create a suspension. Transfer 0. 26 mL 
aluminum hydroxide suspension to a new container (sterile polypropylene microcentrifuge tube or glass vial ). 
2. Add 2.1 mL PBS Diluent. 
3. Add 0.2 mL WEVEE Vaccine.  
4. Invert 5x to mix and hold at ambient temperature for a minimum of 15 minutes. 
5. Withdraw 1.0 mL into a syringe.  
6. Invert 5X to mix immediately prior to administration.  
Preparation of Vaccine with Adjuvant  (30 mcg  + alum )  
1. Gently invert vial of aluminum hydroxide suspension 5x to create a suspension. Transfer 
0.13 mL adjuvant to a new container (sterile polypropylene microcentrifuge tu be or glass 
vial). 
2. Add 0.67 mL PBS Diluent.  
3. Add 0.5 mL WEVEE Vaccine.  
4. Invert 5x to mix and hold at ambient temperature for a minimum of 15 minutes. 
5. Withdraw 1.0 mL into a syringe.  
6. Invert 5X to mix immediately prior to administration.  
 
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 37 of 66 
 
 Preparation of Vacci ne with Adjuvant  (60 mcg  + alum ) 
1. Gently invert vial of aluminum hydroxide  suspension 5x to create a suspension. Transfer 
0.13 mL adjuvant to a new container (sterile polypropylene microcentrifuge tube  or glass 
vial). 
2. Add 0.17 mL PBS Diluent.  
3. Add 1.0 mL WEVEE Vaccine.  
4. Invert 5x to mix and hold at ambient temperature for a minimum of 15 minutes. 
5. Withdraw 1.0 mL into a syringe.  
6. Invert 5X to mix immediately prior to administration.  
7.4    Study Product  Administration  
The vaccine will be prepared in the pharmacy and the prepared syringe containing vaccine will 
be delivered to the clinic for administration.  The study product must be administered within 2 
hours after removing the vial from the freezer.  The plan for product administration is to use 
standard injection technique.  Immediately prior to administration invert the syringe end -over-
end 5x to mix.  The study product will be administered IM into the deltoid muscle by needle and 
syringe.  
7.5    Study Product  Accountability  
7.5.1 Documentation 
The site will be responsible for maintaining an accurate record of the inventory and an accountability record of the investigational study products supplied for this study.  Electronic 
documentation as well as paper cop ies may be used. 
7.5.2 Disposition  
The empty vials and the unused portion of a vial will be discarded on the same day of use in a biohazard containment bag that will be  incinerated or autoclaved  per site policy .  Any unopened 
vials that remain at the end of the study will be discarded at the discretion of the IND Sponsor in accordance with policies that apply to investigational products.  Partially used vials or expired prepared doses cannot be administered to other subjects nor used for in vitro  experimental 
studies and will be discarded as indicated above.  
8 HUMAN SUBJECT PROTECTIONS AND ETHICAL OBLIGATIONS 
This research will be conducted in compliance with the protocol, Good Clinical Practices guidance, and all applicable regulatory requirements. 
8.1    Institutional Review Board  
The protocol, proposed ICF, other written subject information, and any proposed advertising 
material will be submitted to the site IRB for written approval. 
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 38 of 66 
 
 The site PI  must submit and, where necessary, obtain approval from the IRB for all subsequent 
protocol amendments and changes to the ICF.  The site PI is responsible for ensuring proper IRB 
notifications of protocol deviations or SAEs occurring at the site  and other AE reports received 
from the VRC, in accordance with the protocol and the site IRB policy. 
The site PI  will be responsible for obtaining annual IRB approval /renewal throughout the 
duration of the study. Documentation of the IRB approval must be provided to the IND Sponsor. 
8.2    Subject Recruitment  and Randomization   
All study activities will be carried out at the approved study site.  Subjects for this study will be 
recruited through IRB approved advertising by the site in accordance with the site IRB standards 
for recruitment practices.  
Effort will be made to include women and minorities in proportions similar to that of the 
community from which they are recruited.  
8.2.1 Participation of Children 
Children are not eligible to participate in this clinical trial because it is the first study in humans 
with the investigational vaccine and does not meet the guidelines for inclusion of children in 
research according to  45 CFR 46, Subpart D, 401-409.  If the product is assessed as safe and 
immunogenic, other protocols designed for children may be conducted in the future. 
8.2.2 Participation of Site Employees 
The study site will follow institutional policies related to study participation of site employees. 
Neither participation nor refusal to participate will have an effect, either beneficial or adverse, on 
the su bject’s employment or work situation.  
8.3    Informed Consent  
The template  study ICF is provided in Appendix I .  It describes the investigational products to be 
used and all aspects of protocol participation.  Before a subject’ s enrollment in the study, it is the 
investigator’s responsibility to obtain written informed consent from the subject, after adequate explanation of the aims, methods, anticipated benefits, and potential hazards of the study and before any protocol- specif ic procedures or study medications are administered. 
An IRB -approved A ssessment of Understanding ( AoU) quiz, intended to assist in the evaluation 
of the subject’s understanding of this study, is administered as part of the consent process.  The 
AoU should be completed prior to randomization, and verbalized understanding of all questions 
answered incorrectl y should be confirmed with a subject. 
The acquisition of informed consent will be documented in the subject’s medical records, as 
required by 21 CFR 312.62, and the ICF will be signed and personally dated by the subject and 
by the person who conducted the informed consent discussion.  The original signed ICF will be 
placed in the medical record and a copy of the signed ICF will be provided to the subject. 
8.4    Subject Confidentiality  
The site investigator must ensure that the subject’s anonymity is maintained, and will ensure that no information identifying the subject will be released to any unauthorized party.  Personally 
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 39 of 66 
 
 identifiable information will not be identified in any reports on this study.  All records will be 
kept confidential to the extent provided by federal, state and local law.  Medical records are 
made available for review when required by the FDA or other authorized users, such as the 
vaccine manufacturer, only under the guidel ines set by the Federal Privacy Act.  Direct access 
includes examining, analyzing, verifying, and reproducing any records and reports that are 
important to the evaluation of the study.  The investigator is obligated to inform the subjects that 
the above na med representatives will review their study -related records without violating the 
confidentiality of the subjects .  Stored study research samples are labeled by a code (such as a 
number) that only the study team can link to the subject. The requirement to maintain subject 
confidentiality is included in the study informed consent document. 
8.5    Risks and Benefits  
8.5.1 Risks of the WEVEE Vaccine  
There is no prior human experience with administration of VRC -WEVVLP073-00- VP in healthy 
adults.  First human clinical trials of a similar VLP vaccine, VRC 311 - CHIKV VLP, determined that doses in the range  of 10 -40 mcg were safe for further evaluation in healthy 
adult s.  The solicited local and systemic signs and symptoms following administration of the 
CHIKV VLP were generally none to mild.  In VRC 311, seven laboratory test AEs (occurring in 
four participants) were assessed as related to study vaccine based on temporal relationship to 
vaccination.  The AEs included four m ild transient alanine aminotransferase increases and two 
mild and one moderate transient neutropenia.  All resolved without clinical sequelae.   
This alphavirus CHIKV VLP vaccine was advanced to Phase 2 clinical evaluation in November 
2015 in protocol VRC 704. As of November 13, 2017, 400 subjects have received a total of 780 
injections of VRC- CHKVLP059 -00-VP or placebo.  There have been no serious adverse events 
(SAEs) assessed as related to the study product reported in the study and no AEs that required 
expedited reporting to the FDA.  Abnormalities in blood laboratory parameters observed in the 
study were asymptomatic, predominantly mild or moderate in severity . The local and systemic 
reactogenicity  signs and symptoms following administration of the CHIK V VLP were generally 
mild to moderate .  All a bnormalities in blood laboratory parameters, solicited local and systemic 
reactogenicity signs and symptoms were resolved without clinical  sequelae.  
Potential side effects resulting from IM injection include stinging, arm discomfort, redness of the skin or mild bruising at product administration sites.  
Subjects may exhibit general signs and symptoms associated with administration of a vaccine, including fever, chills, rash, aches and pains, nausea, headache, dizz iness and fatigue. These side 
effects will be monitored, but are generally short term, mild to moderate severity and usually do not require treatment.  
There may be other unknown side effects. 
8.5.2 Risks of Aluminum Hydroxide Suspension  
Aluminum is the most common adjuvant used in human vaccines licensed by the FDA [ 27] used 
in literally billions of individuals over decades of clinical use [ 14].  Adverse effects  are generally 
limited to minor local reaction at the injection site  [14].  Other more severe local reactions like  
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 40 of 66 
 
 erythema, subcutaneous nodules, contact hypersensitivity and granulomatous inflammation may 
occur  [28].   
8.5.3 Risks of Phosphate Buffered Saline  
PBS will be used as a diluent for the vaccine.  No AEs are anticipated from the use of this 
product.  
8.5.4 Other Risks  
Blood collection procedures are common in routine medical practice.   The risks of blood sample 
collection are minimal and consist of mild discomfort at the blood collection site.  The procedure 
may cause mild pain, bruising, fainting, and, rarely, infection at the blood collection site.  
We do not know the possible effects of the study vaccine on the fetus or nursing infant. Therefore, females of childbearing potential will be tested for  pregnancy prior to each product 
administration.  
It is possible that the standard medical tests performed as part of this research protocol will result in new diagnoses. Depending on the medical findings and consequences of being provided with 
the new medi cal information about health status, the study subject may view this aspect of study 
participation as either a risk or a benefit. Any such information will be shared and discussed with 
the subject and, if requested by the subject, will be forwarded to the subject’s primary health care provider for further workup and management. 
8.5.5 Benefits  
Study subjects will not receive direct health benefit from study participation.  This protocol is not 
designed to provide treatment for any condition.  Others may benefit fr om knowledge gained in 
this study that may aid in the development of the WEVEE vaccine.   The investigational vaccine 
is not expected to provide protection from WEEV, EEEV, and VEEV infection. 
8.6    Plan for Use and Storage of Biological Samples  
To be eligible  for this protocol, subjects must be willing to allow stored specimens to be used in 
the future for studying infectious diseases, immune function, vaccine responses, and other 
medical conditions.  If tests show evidence of any acute or chronic condition, s ubjects will be 
informed of the results and advised to seek appropriate medical care for the condition.  In 
general, testing performed at a research laboratory is not for diagnostic purposes and results will 
not be available to the study site or study subj ect. 
The plan for use and storage of biological samples from this protocol is as outlined in the following sections. 
8.6.1 Use of Samples, Specimens and Data  
Samples, specimens and data collected under this protocol may be used to conduct protocol-
related safety  and immunogenicity evaluations, exploratory laboratory evaluations related to the 
type of infection the vaccine was designed to prevent, exploratory laboratory evaluations related 
to vaccine research in general and for research assay validation.  Genetic testing will not be 
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 41 of 66 
 
 performed in  this study, but may be performed  on stored samples at later time as needed,  in 
accordance with the genetic testing information that is  included in the study informed consent. 
8.6.2 Storage and Tracking of Blood Samples and Other Specimens  
All of the stored study research samples are labeled by a code that only the site can link to the 
subject.  Samples will be collected  at sites and shipped in batches to Battelle where these 
samples will be kept in  secure facilities with limited access.  
Data will be kept in password-protected computers.  Only investigators or their designees will 
have access to the samples and data. Samples will be tracked in the Laboratory Information 
Management System (LIMS) database or using another software designed for this purpose (e.g., Freezerworks).  
8.6.3 Disposition of Samples, Specimens and Data at Completion of the Protocol  
In the future, other investigators (both at NIH and outside) may wish to study these samples and/or data.  IRB approval must be sought prior to any sharing of samples.  Any clinical information shared about those samples would similarly require prior IRB approval.  The 
research use of stored, unlinked or unidentified samples may be exempt from the need for 
prospective IRB review and approval.  Exemption requests will be submitted in writing to the NIH Office of Human Subjects Research, which is authorized to determine whether a research activity is exempt.  
At the time of protocol termination, samples will either remain in the contracted central repository, or IND S ponsor laboratories or, after IRB approval, samples may be transferred to 
another repository.  Data will be archived by the IND Sponsor in compliance with requirements 
for retention of re search records, or after IRB and the IND Sponsor approval, it may be either 
destroyed or transferred to another repository. 
8.6.4 Loss or Destruction of Samples, Specimens or Data  
Any loss or unanticipated destruction of samples (for example, due to freezer malfunction) or 
data (for example, misplacing a printout of data with identifiers) that compromises the scientific integrity of the study will be reported to the site IRB in accordance with institutional policies.   
The site  PI will also notify the site IRB if the decision is made to destroy the remaining samples.  
8.7    Subject Compensation  
Subjects will be compensated for time and inconvenience of study participation in accordance 
with the site -specific IRB approved plan . The total compensation is included in the site -specific 
informed consent document. 
8.8    Safety Monitoring  
8.8.1 Protocol Safety Review Team  
The site PI  is responsible for ensuring daily review of the site’s clinical safety data as it becomes 
available.  The PSRT includes the IND Medical Officer  or designee, the study Protocol Chairs, 
and the site PI  or designee.    
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 42 of 66 
 
 The PSRT will review the summary study s afety data reports weekly from initiation of the study 
through 4 weeks after the last subject receives  the last  product administration, and will continue 
to monitor the safety data reports on a monthly basis through completion of the last study visit,  
in order to be certain that the investigational vaccine has an acceptable safety profile.   The PSRT 
will be notified and convened to review any study pauses and to conduct safety reviews for a 
dose escalation .  
9 ADMINISTRATIVE AND L EGAL OBLIGATIONS  
9.1    Protocol Amendments and Study Termination  
Protocol amendments must be made only with the prior approval of the  IND Sponsor VRC , 
NIAID .  Agreement from the site  PI must be obtained for all protocol amendments and 
amendments to the ICF.  All study amendments will be submitted to the IRB for approval. 
The VRC Protocol Study Chairs, the site  IRB, NIAID and the FDA reserve  the right to terminate 
the study.  The IND Sponsor  will notify the site IRB in writing of the study’s completion or 
early terminat ion. 
9.2    Study Documentation and Storage  
The site PI will maintain a list of appropriately qualified persons to whom trial duties have been 
delegated . 
Source documents are original documents, data, and records from which the subject’s data are obtained.  Th ese include but are not limited to hospital records, clinical and office charts, 
laboratory and pharmacy records, radiographs, and correspondence.  
The site PI  and staff are responsible for maintaining a comprehensive and centralized filing 
system of all essential study -related  (essential)  documentation, suitable for inspection at any time 
by representatives from the VRC, IRB, FDA, and/or applicable regulatory authorities.  Elements 
include: 
• Subject files containing completed informed consent forms, and supporting copies of source documentation (if kept), and 
• Study files containing the protocol with all amendments, IB, copies of all 
correspondence with the IRB and VRC 
All essential documentation should be retained by the  institution for the same period of ti me 
required for medical records retention.  The FDA requires study records to be retained for up to two years after marketing approval or refusal (21 CFR 312.62).  No study document should be destroyed without prior written agreement between the IND Sponsor,  and the site  PI.  Should the 
investigator wish to assign the study records to another party or move them to another location, they must notify the IND Sponsor in writing of the new responsible person and/or the new location. 
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 43 of 66 
 
 9.3    Data Collection and Prot ocol Monitoring 
9.3.1 Data Collection 
Clinical research data will be collected in a secure electronic web -based clinical data 
management system through a contract research organization, Emmes Corporation, Rockville, 
MD.  Extracted data without patient identifiers will be sent to the Protocol Statistician for statistical analysis.  
9.3.2 Data Sharing Plan 
Data generated in this study will be shared as de-identified data in the government-funded public repository, www.ClinicalTrials.gov.  Data may be shared prio r to publication at approved public 
presentations or for collaborative development and will be shared at the time of publication or within 1 year of the primary completion date. 
9.3.3 Source D ocuments  
The site will maintain appropriate medical and research records for this trial, in compliance with 
International Conference on Harmonization – Good Clinical Practice ( ICH-GCP ), regulatory and 
institutional requirements for the protection of confidentiality of  subjects.  
Source data are all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary for the reconstruction and evaluation of the trial.  Examples 
of these original documents and data records include, but are not limited to, medical  records, 
laboratory reports, pharmacy records and other research records maintained for  the clinical trial.  
9.3.4 Protocol Monitoring Plan 
The VRC/ NIAID or their authorized representatives are responsible for contacting an d visiting 
the site investigator for the purpose of inspecting the facilities and, upon request, inspecting the 
various records of the trial, provided that subject confidentiality is respected. 
Site investigators will allow the study monitors, the site  IRB, and the FDA to inspect study 
documents ( e.g., ICF, drug distribution forms, and case report forms) and pertinent hospital or 
clinic records for confirmation of the study data. Site visits by study monitors will be made in accordance with the study monito ring plan to 
monitor the following: study operations, the quality of data collected in the research records, the 
accuracy and timeliness of data entered in the database, and to determine that all process and regulatory requirements are met.  Study monitoring visits will occur as defined by the IND Sponsor approved monitoring plan. 
9.4    Language  
All written information and other material to be used by subjects and investigative staff must use 
vocabulary and language that are clearly understood.  
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 44 of 66 
 
 9.5    Policy Regarding Research-Related Injuries  
The research site will provide short- term medical care for any injury resulting from participation 
in this research.   In general, the NIH , the research site, or the Federal Government will provide 
no long- term medical care or financial compensation for research -related injuries.  
9.6    Site Management  
The IND Sponsor is responsible for overall study management.  Assistance in managing the 
study is being provided by specific Sponsor representatives as per contractural obligations. 
The site that will be enrolling and vaccinating study subjects will have a site PI .  A PI is defined 
as an individual who actually conducts a clinical investigation  at a study site and under whose 
immediate direction the study product is administered to subjects .  The PI is required to conduct 
the study in compliance with all applicable regulations and good clinical practices.   
The site will be required to obtain a loca l IRB approval for the protocol, all protocol 
amendments, and study supplementary documentation as per the site IRB requirements. 
Publication of any study related information is governed by VRC, NIAID, NIH policies. 
Specifically, neither the CROs nor site personnel may submit for public presentation any meeting abstract or manuscripts without prior review  by VRC.  
  
   
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 45 of 66 
 
 10 REFERENCES  
1. Griffin, D.E., Alphaviruses , in Fields Virology , D.M. Knipe and P.M. Howley, Editors., 
Lippincott Williams & Wilkins; 2007. p. 1023-67. 
2. CDC, Category A and B Biological Agents. Public Health Preparedness: Mobilizing State 
by State, 2008. 
3. Zacks, M.A. and S. Paessler, Encephalitic alphaviruses. Veterinary Microbiology, 2010. 
140(3 –4): p. 281-286. 
4. Dupuy, L.C. and D.S. Reed, Nonhuman primate models of encephalitic alphavirus 
infection: historical review and future perspectives. Current Opinion in Virology, 2012. 2(3): p. 363-367. 
5. Bale, J.F., Jr., Viral encephalitis.  Med Clin North Am, 1993. 77(1): p. 25-42. 
6. Weaver, S.C. and W.K. Reisen, Present and future arboviral threats. Antiviral Res, 
2010. 85(2): p. 328-45. 
7. Smith, D.W., J.S. Mackenzie, and S.C. Weaver, Alphaviruses , in Clinical Virology, Third 
Edition . 2009, American Society of Microbiology. 
8. Akahata, W., et al., A virus -like particle vaccine for epidemic Chikungunya virus protects 
nonhuman primates against infection. Nat Med, 2010. 16(3): p. 334-8. 
9. Chang, L.J., et al., Safety and tolerability of chikungunya virus- like particle vaccine in 
healthy adults: a phase 1 dose- escalation trial.  Lancet, 2014. 384(9959): p. 2046-52. 
10. Brewer, J.M., (How) do aluminium adjuvants work? Immunol Lett, 2006. 102(1): p. 10-5. 11. Kuroda, E., C. Coban, and K.J. Ishii, Particulate adjuvant and innate immunity: past 
achievements, present findings, and future prospects. Int Rev Immunol, 2013. 32(2): p. 209-20. 
12. FDA. Common Ingredients in U.S. Licensed Vaccines . 2014; Available from: 
http://www.fda.gov/biologicsbloodvaccines/safetyavailability/vaccinesafety/ucm187810.htm. 
13. He, P., Y. Zou, and Z. Hu, Advances in aluminum hydroxide-based adjuvant research 
and its mechanism. Hum Vaccin Immunother, 2015. 11(2): p. 477-88. 
14. Brito, L.A., P. Malyala, and D.T. O'Hagan, Vaccine adjuvant formulations: a pharmaceutical perspective. Semin Immunol, 2013. 25(2): p. 130-45. 
15. Brito, L.A. and D.T. O'Hagan, Designing and building the next generation of improved 
vaccine adjuvants. J Control Rele ase, 2014. 190: p. 563-79. 
16. Schijns, V.E. and E.C. Lavelle, Trends in vaccine adjuvants. Expert Rev Vaccines, 2011. 
10(4): p. 539-50. 
17. Oleszycka, E. and E.C. Lavelle, Immunomodulatory properties of the vaccine adjuvant 
alum. Curr Opin Immunol, 2014. 28: p. 1-5. 
18. Roldao, A., et al., Virus -like particles in vaccine development.  Expert Rev Vaccines, 
2010. 9(10): p. 1149-76. 
19. Roy, P. and R. Noad, Virus -like particles as a vaccine delivery system: myths and facts.  
Hum Vaccin, 2008. 4 (1): p. 5-12. 
20. Pittman, P. and S.A. Plotkin, Biodefence and Special Pathogen Vaccines , in Vaccines, 
5th ed., S.A. Plotkin, W.A. Orenstein, and P.A. Offit, Editors., Elsevier; 2008: Philadelphia, PA. p. 1123-33. 
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 46 of 66 
 
 21. Pittman, P.R., et al., Long -term duration of detectable neutralizing antibodies after 
administration of live-attenuated VEE vaccine and following booster vaccination with 
inactivated VEE vaccine.  Vaccine, 1996. 14(4): p. 337-43. 
22. McClain, D.J., et al., Immunologic interference from sequential administration of live 
attenuated alphavirus vaccines. J Infect Dis, 1998. 177(3): p. 634-41. 
23. Calisher, C.H., D.R. Sasso, and G.E. Sather, Possible evidence for interference with 
Venezuelan equine encephalitis virus vaccination of equines by pre-existing antibody to Eastern or Western Equine encephalitis virus, or both. Appl Microbiol, 1973. 26(4): p. 485-8. 
24. Pittman, P.R., et al., Immune interference after sequential alphavirus vaccine 
vaccinations. Vaccine, 2009. 27(36): p. 4879-82. 
25. Reisler, R.B., et al., Immune interference in the setting of same-day administration of two 
similar inactivated alphavirus vaccines: Eastern equine and western equine encephalitis. Vaccine, 2012. 
26. Clements, C.J. and E. Griffiths, The global impact of vaccines containing aluminium 
adjuvants. Vaccine, 2002. 20 Suppl 3 : p. S24-33. 
27. Petrovsky, N. and J.C. Aguilar, Vaccine adjuvants: current state and future trends. 
Immunol Cell Biol, 2004. 82(5): p. 488-96. 
28. Baylor, N.W., W. Egan, and P. Richman, Alumi num salts in vaccines --US perspective.  
Vaccine, 2002. 20 Suppl 3 : p. S18-23. 
29. Gupta, R.K., et al., Adjuvant properties of aluminum and calcium compounds. Pharm 
Biotechnol, 1995. 6: p. 229-48. 
30. Chackerian, B., Virus -like particles: flexible platforms for vaccine development.  Expert 
Rev Vaccines, 2007. 6(3): p. 381-90. 
   
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 47 of 66 
 
 APPENDIX I:  STUDY INFORMED CONSENT FORM 
The template  informed consent form is provided to guide development of a site- specific consent  
form. Only IRB-approved consent forms will be used to consent subjects for study participation. 
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 48 of 66 
 
 Template: Study Informed Consent Form  
 
STUDY TITLE: VRC 313  
A Phase 1 Open Label, Dose- Escalation Clinical Trial to Evaluate the Safety and  
Immunogenicity of a Trivalent Virus- Like Particle (VLP) Encephalitis  Vaccine, VRC  
WEVVLP073-00- VP, in Healthy Adults . 
INTRODUCTION 
We invite you to take part in a research study at the  [Insert Site name  here]   
The study is sponsored by the National Institutes of Health (NIH) in Bethesda, MD, USA.  You 
can decide if you want to take part in this study or not. There is no penalty or loss of benefits if you choose not to take part .  Please ask questions and talk about this study with anyone you 
want.   Take as much time as you need to decide.  You will be given a copy of this consent form. 
SCREENING  
Before you can take part in this experimental study, your health will be checked so we can decide if you qualify to participate .  You will need to sign this consent form before screening.  If 
you qualify, then you may take part in the vaccine study. 
Screening includes a physical exam and blood tests to check your health.  We will ask you about 
your health history.  If you are a female who is able to have children, you will be asked about the possibility of you becoming pregnant while in the study.  You will be tested for pregnancy and for HIV .  During screening, we will collect some blood to store for research.  We will review the 
test results with you and tell you if the results show that you are eligible to join the study.   
PURPOSE OF THE STUDY  
This is the first study in people of this experimental vaccine for the prevention of Western  equine 
encephalitis virus , Eastern  equine encephalitis virus, and Venezuelan equine encephalitis virus 
infection.  The word “Encephalitis” means swelling of the brain, which occurs in some people who get infected by these viruses.   “Experimental” means that the Food and Drug Administration 
(FDA) has not approved this study vaccine for general use in the public.  The FDA  allows it to 
be used for research only.  We do not know if this  vaccine works.   The main purpose of this 
study is to see if the experimental vaccine is safe and  if there are any side effects.  We also want  
to study the immune response to this vaccine.  
BACKGROUND   
These 3 viruses were first seen in horses, that’s  why they were  named “equine”.   Western, 
Eastern and Venezuelan equine encephalitis viruses are very similar to each other and cause a 
similar type of disease in humans.  The virus es are passed to humans by mosquitoes.  Infection 
from these viruses can cause fever, chil ls, discomfort, feeling sick, muscle pain and then 
headache, vomiting, restlessness, irritability, seizures , coma and death.  
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 49 of 66 
 
 STUDY PRODUCTS  
Vaccines are given to teach  the body to prevent or fight an infection.  In this study , we are testing 
an experimental  vaccine that was developed by the Vaccine Research Center (VRC) at the NIH. 
It is named  VRC -WEVVLP073 -00-VP, but is  also called  the “WEVEE ” vaccine .  This vaccine 
is intended to help the body to make an immune response to Western, Eastern and Venezuelan 
equine encephalitis viruses. 
The WEVEE vaccine: Most vaccines are made of proteins that are injected into a muscle. 
Proteins are natural substances that  the body and viruses use as building blocks. The WEVEE 
vaccine is a type of vaccine known as a virus- like particle (VLP)  vaccine. This is  because it is 
made up of  proteins from  the Western, Eastern and Venezuelan equine encephalitis viruses that 
make particles that look like the outside surface of these 3 viruses. The body’s immune system may respond to these particles by making cells to fight off these viruses .  
However, there are no live or killed viruses in the vaccine, so you cannot get infect ed with any of 
these 3 viruses from getting the vaccine.  This is the first study to give th e WEVEE vaccine to 
humans.  You should not expect this experimental vaccine to protect you from Western, Eastern and Venezuelan equine encephalitis viruses infection. 
Some people in this study will get the WEVEE vaccine mixed with another study product called 
an adjuvant. Adjuvants are substances that may make your body’s response to the vaccine better.  The 
adjuvant in this study will be  alum inum hydroxide (alum).   Alum  has been used for over 60 years 
in billions of vaccinations with licensed vaccines and has been found to be safe.  The use of alum as an adjuvant in this study has been reviewed and approved by the FDA. 
ELIGIBILITY  
You are eligible to take part  in this study if  you are: 
• between 18 and 50 years of age  
• in general good health without significant medical problems  
• willing to get  the WEVEE vaccine  
• willing to give b lood samples for future research  
• additionally, if you are a female who is able to  become pregnant: willing to use birth 
control from at least 21 days before randomization through the end of the study 
STUDY PLAN  
About 30 people will take part in this study.  You will be in the study for about 36 weeks (8 
months) and have about 9 clinic visits and 2 telephone contacts .  You will get 2 vaccinations, 
each by injection (shot) in the upper arm muscle.  This is called an intramuscular “IM” injection.  
We will check you for any side effects from the vaccine.    
We will tell you if we learn anyth ing new during this study that might cause you to change your 
mind about staying in the study.  At the end of the study, we will tell you when study results may be available and how to learn about them. 
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 50 of 66 
 
 If you agree to take part in the study, you will be randomly assigned (like pulling a number from 
a hat) to get either : 
• The WEVEE vaccine alone (Group 1, Group 3, and Group 5) or,  
• The WEVEE vaccine mixed with alum (Group 2, Group 4, and Group 6).  
Once enrolled, you will know which group you are in.  
The study will start by randomizing people to get a dose of 6 mcg in Group 1 or Group 2.  We 
will review the data after about 2 weeks to make sure th is vaccine dose has no safety concerns  
before we star t randomizing people to get the next dose of 30 mcg in Group 3 or Group 4. We 
will review the data for this dose after about 2 weeks to make sure this  vaccine dose has no 
safety concerns  before we start randomizing people to the 60 mcg dose in Group 5 or Group 6. 
The table below shows the vaccination plan: 
VRC 313  
Group  Subjects  Dose  Day 0  Week 8  
1 5 6 mcg  WEVEE  WEVEE  
2 5 WEVEE + alum  WEVEE + alum  
3 5 30 mcg WEVEE  WEVEE  
4 5 WEVEE + alum  WEVEE + alum  
5 5 60 mcg WEVEE  WEVEE  
6 5 WEVEE + alum  WEVEE + alum  
Total  30  
STUDY PROCEDURES  
Each vaccination visit will take about 4  to 6 hours.  Other clinic visits will take about 1 to 2 
hours.  The clinic staff will watch  you for at least 30 minutes after each vaccination.   
If you are a woman who is able to get pregnant, we will do a pregnancy test before each injection.  The test must show that you are not pregnant to get the injection.  
You will have a telephone call ab out 2 days after each vaccin ation  so we  can check on you.   
You will need to complete a diary card at home for 7 days after each vaccination .  The purpose 
of the diary card is so you can write down  any symptoms that the vaccine may cause.   We will 
ask you to record your temperature daily and look at the injection site on your arm each day .  We 
will give you a thermometer to measure your temperature and a ruler to measure any skin 
changes at the injection site.   You will get a  password  to a secure website to enter this data 
online.  If you do not have access to the internet , you may use a paper diary card instead.  
If you have any side effects, you should tell a clinic nurse or doctor as soon as possible.  You can 
reach the staff by phon e 24 hours a day.  If you have symptoms, you may be asked to come to 
the clinic for an examination before your next scheduled visit.  With your consent, we may take a photograph of any reactions you have to the vaccine.   It is very important that you follo w the 
instructions from the clinic staff.  
At each visit, we will check  you for any health  changes or problems.  We will ask you how you 
are feeling and if you have taken any new medications.  We will draw your blood at each visit, taking up to 5 tubes of blood.  We will tell you right away if any of your test results show a 
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 51 of 66 
 
 health problem.  Some blood samples will be used for research only, to study your immune 
response to the vaccine.  Results of these research tests are not used to check your health and will not be given to you. 
MONITORING OF THE STUDY 
This study will be monitored by a  group of physicians and scientists associated with the NIH .  
This group will review the study information  and will pay close attention to  any reactions.   If 
there are serious side effects,  study injections may be delayed or canceled.  
Your research study charts  may be reviewed by the IND Sponsor representatives .   
GENETIC TESTING  
Some genetic tests are done in research studies to see if genetic differences in people cause 
different types of immune responses.  G enetic testing will not be done in this study, but may be 
performed on stored samples at later time .  If genetic tests are done at a later time, your name 
and identifying information  will not be on your samples and the results will not be in your 
medical record.  These tests are not used to check your health and we will not tell you the results.  
STORED SAMPLES  
Some of the blood we draw from you during the study will be used by investigators to study 
proteins and other molecules that may be involved in the immune response. Blood samples  will be stored for future re search to learn more about WEVEE, vaccines, the immune system, and/or 
other medical conditions. 
The results from the research done with your stored samples are not meant to be used for medical 
care.  They will not be given to your health care provider and will not be put in your medical record.  
You may not take part  in this study if you are not willing to have your blood samples stored for 
future analysis.  
Labeling of Stored Samples :  Your stored samples will be labeled by a special code or number 
and not your personal information.  Only the study team can link this code to you.  Any 
identifying information about you (like name or date of birth) will be kept as confidential as   
allowable  by law.  
Risks from Stored Samples :  The re is a risk of unplanned release of information from your 
medical records.  The chance that this information will be given to an unauthorized person 
without your permission is very small.  Possible problems with the unplanned release of information include discrimination  when applying for insurance or employment.  Similar 
problems may occur if you give  information yourself or agree to have your medical records 
released.  
Future Studies :  In the future, other investigators at NIH or outside of NIH may wish to study 
your sto red samples.  When the study team shares your stored samples, they will be marked with 
a code, but will not have any identifying information on them.  Some information about you, like your gender, age, health history, or ethnicity may also be shared with o ther researche rs.  Any 
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 52 of 66 
 
 future research studies using your samples will be conducted in a way  that protects  the rights and 
privacy of study participants . 
Your stored samples will be used only for research and will not be sold.  The research done with 
your s amples  may be used to make new products in the future, but you will not get payment for 
such products. 
Making your Choice: You cannot take part in this study if you do not want us to collect or store 
your blood samples. If you agree to take part in this study, you must also agree to let us keep any of your samples for future research.  
HUMAN DATA SHARING  
To advance science, it is helpful for researchers to share information they get from studying humans by putting it into shared scientific databases.   Researchers can then study the information 
combined from many studies to learn even more about health and diseases.  
If you agree to take part in this study, some of your data will be placed into one or more 
scientific databases.  We will remove identify ing information like your name, address, and birth 
date.  The data may then be used for future research and shared broadly for research purposes.  Only researchers who are approved to access the database may be able to see and use your information. You wil l not get any direct benefits from future research that uses your data and 
information.  
POSSIBLE STUDY RISKS  
Possible  risks of injections:  Temporary stinging, pain , redness, soreness, itchiness, swelling, 
bruising, or a cut in the arm.  There is a very s mall chance of infection.  
Possible  risks of any vaccine:  Fever, chills, rash, aches and pains, nausea, headache, dizziness, 
and feeling tired and/or unwell.  These reactions are usually greatest within the first 24 hours 
after vaccination and typically last 1 to 3 days.  Over-the-counter medicine, like acetaminophen 
(Tylenol) or ibuprofen, may be used to help relieve these symptoms.   
Very rarely, a serious allergic reaction may occur shortly after any vaccination.  This is called 
“anaphylaxis” and may be life -threatening.  While you are waiting in the clinic after the 
vaccination, we will watch you for anaphylaxis.  Treatment for anaphylaxis will be given right 
away if it occurs.   
Possible  risks  of blood d rawing :  Pain, bleeding, bruising, feeling lightheaded, fainting , or 
rarely, infection at the site where the blood is taken. 
Possible  risks of WEVEE  Vaccine:   The WEVEE  vaccine has not been given to people before 
and it may have unknown risks or side effects .  It has been tested in mice  and monkeys.  The 
vaccine did not have any severe side effects and met the safety criteria to be tested in humans.  In 
a study  of a similar product, a chikungunya virus VLP vaccine was well tolerated with no 
reported joint pain or fever after vaccination.  No seri ous adverse events were reported .   
Possible  risk of aluminum hydroxide s uspension:   Aluminum adjuvants have been found to be 
safe for over 60 year s.  Aluminum-containing vaccines have been associated with reactions of 
the skin (erythema), bumps in the skin (subcutaneous nodules), contact hypersensitivity and 
small nodular skin lesions.   
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 53 of 66 
 
 Possible r isks during Pregnancy :  We do not know the possible effects of the study vaccines on 
a fetus or nursing infant.  Women who are able to become pregnant must have a negative 
pregnancy test before each study injection and agree to practice adequate birth control beginning at least 21 days before getting the first injection until the last study visit.   If you are pregnant, 
breast -feeding or want to become pregnant during the next 36 weeks, you cannot take part .  
You must also tell the clinic if you think that you are or might  be pregnant during this study.  If 
you become pregnant, you will not get any  more  injections.  However, you will be asked to 
continue with follow- up visits so we can check your health .  You will also  be asked about the 
outcome of your pregnancy.  
Possible  other r isks:  The safety of the vaccine tested  in this study is unknown.  It is unknown if 
the study injection will affect how you respond to any future infection with WEVEE or to any other WEVEE vaccines that you may get in the future. 
You may not donate blood at a blood bank while taking part in this study .  You may not donate 
blood for one year after your last study in jection.  
POSSIBLE BENEFITS  
This study is not designed to benefit you or protect you from infection from these viruses.  Others may benefit in the future from the information that will be learned from the study . 
COSTS TO YOU FOR YOUR PARTICIPATION 
There are no costs to you for taking part  in this study.  We will not charge you or your insurance 
carrier for any health evaluations or services.  You or your health insurance will have to pay for 
all costs for m edical care that you get outside this study.  It is possible that you may  have some 
costs  that are not covered by the study compensation we give you . 
COMPENSATION TO YOU FOR YOUR PARTICIPATION  
You will be compensated for your time and inconvenience as follows:  [insert site plan].  This 
will be based on the number of study visits you attend and study injections you get. 
Actual compensation is based on the number and type of study visits you finish.  Your compensation may need to be reported to the Internal Revenue Service (IRS) as taxable income.  
REASONS FOR REMOVING YOU FROM THE STUDY WITHOUT YOUR CONSENT  
The study doctor can take you out of this study without your consent if:  
• You don't keep appointments or follow study procedures. 
• You get a serious illness that needs ongoing medical care.  
• You need to get treatment with a medication that affects your immune system (such as a steroid like prednisone) 
• You enroll in another research study at the same time you are in this study. 
• You become pregnant. 
• The study is stopped by regulatory agencies, the study sponsor or study investigators. If  
this happens, we will tell you why . 
If you agree to take part in this study, it is important for you to keep all of your appointments. 
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 54 of 66 
 
 Your participation in this study is completely voluntary.  You can  choose to stop taking part in 
the study at any time.   There is no penalty or loss of benefits for choosing to leave the study.  
If you get the first injection but not the second, we still want you to continue with all planned 
follow-up visits until the end of the study.  It is important that we continue to check your health even if you do not get the second vaccination . 
ALTERNATIVE S 
This study is not designed to treat or prevent any disease.  You may choose not to take part  in 
this study.  You may be eligible for other studies.  
CONFLICT OF INTEREST  
[Insert site specific COI information ]. 
The NIH developed the investigational product being used in this research study.  The results of 
this study could play a role in whether the FDA will approve the study product for sale at some time in the future.  If approved, the future sale of the study product could lead to payments to NIH and some NIH  scientists.   By U.S. law, government scientists are required to get  such 
payments for their inventions.  You will not get any money from the development or sale of the product.   
CLINICALTRIALS.GOV 
A description of this clinical trial will be availa ble on www.ClinicalTrials.gov
. This website 
will not include information that can identify you.  At most, the website will include a 
summary of the results.  You can search this website at any time.   
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 55 of 66 
 
 OTHER PERTINENT INFORMATION 
1. Confidentiality.  When results of an NIH research study are reported in medical journals or at 
scientific meetings, the people who take part are not named and identified.  In most cases, the [name 
of the institution]  will not release any information about your research involvement without your 
written permission.  However, if you sign a release of information form, for example, for an insurance company, the [name of institution]  will give the insurance company information from your medical 
record.  This information might aff ect (either favorably or unfavorably) the willingness of the 
insurance company to sell you insurance.   
The Federal Privacy Act protects the confidentiality of your medical records.  However, you should 
know that the Act allows release of some information from your medical record without your 
permission, for example, if it is required by the Food and Drug Administration (FDA), members of Congress, law enforcement officials, or other authorized people.  
2. Policy Regarding Research -Related Injuries.  The research site will provide short- term medical 
care for any injury resulting from your participation in research here.  In general, no long- term 
medical care or financial compensation for research -related injuries will be provided by the NIH, 
the research site, or the Federal Government.  However, you have the right to pursue legal remedy if you believe that your injury justifies such action.   
3. Payments.  The amount of payment to research volunteers is guided by the [insert name of 
institution]  policies.  In genera l, patients are not paid for taking part in research studies at the insert 
name of institution ].  Reimbursement of travel and subsistence will be offered consistent with 
[insert name of institution] guidelines. 
4. Problems or Questions.  If you have any problems or questions about this study or about any 
research -related injury, contact the Principal Investigator, ____, or the Study Coordinator , ___.     
5. Consent Document.  Please keep a copy of this document in case you want to read it again.  
COMPLETE APPROPRI ATE ITEM(S) BELOW:  
Adult Study Participant’s Consent   
I have read the explanation about this study and have been given the opportunity to discuss it and to ask questions.  I 
hereby consent to take part in this study.  
    
                                         
                          
Signature of Adult Participant                                                        Time  
  
Print Name  
   
Date  
THIS CONSENT DOCUMENT HAS BEEN APPROVED FOR USE  
FROM XXXXXX THROUGH XXXXXX. 
     
Signature of Investigator/                                
Person Obtaining Consent                              
 
  
Print Name  Signature of Witness                                      Date  
 
 
  
Print Name  
 
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 56 of 66  
  
 
 
  
APPENDIX II:  CONTACT INFORMATION  
   
 
  
 
 
P
RODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
P
age 57 of 66  
  
 
 
- -  
 
 
 
  
 
 
 
 
- -  
 
 
 
  
 
 
  
 
 
 
 
 
 
 
   
 
 
 
 
  
 
 
 
 
  
 
  
 
 
 
  
 
 
- -  
 
  
 
- -  
 
 
- -  
 
 
- -  
 
 
 
  
 
 
  
 
 
 
 
 
 
- -  
 
 
- -  
 
 
- -  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   

PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 58 of 66  
 APPENDIX III: SCHEDULE OF EVALUATIONS  
 
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 59 of 66  
  Screen  VRC 313 Schedule of Evaluations  
Visit  *01 02 02A 03 04 05 05A 06 07 08 09 
Week of Study  -4 to 0 W1 W1 W2 W4 W8 W9 W10  W12  W24  W36  
Day of Study  -28 to 0 D01 D2 D14 D28 D56 D58 D70 D84 D168  D252  
Clinical  Tube             
VRC 313 Informed  Consent   X           
VRC 313 AoU   X           
2 Physical exam  for eligibility, height /weight  /vital signs and 
targeted exam (as needed) at other visits.   X X  X X X  X  X  X  X  
Medical history targeted to eligibility at screening; then 
interim medical history   X X  X X X  X  X  X  X  
3Study  product administration    X    X      
Phone evaluation (clinic visit as needed)     X    X     
Begin 7-Day Diary Card    X    X      
4Pregnancy test: urine (or serum)   X X    X    X  
Counseling on pregnancy prevention/  Reproductive 
Information Form   X X  X  X  X  X  X  X X 
CBC, differential, platelet count  EDTA  3 3  3 3 3  3 3 3 3 
ALT SST 4 4  4 4 4  4 4 4 4 
Creatinine  SST X X    X      
HIV ELISA (Western blot or PCR, if needed)  SST 4           
Research              
Antibody assays and serum  SST *16 32  16 32 32  16 32 16 16 
Daily Volume (mL)   27 39 0 23 39 39 0 23 39 23 23 
Max. Cumulative Volume (mL)   27 66 66 89 128 167 167 190 229 252 275 
* Screening:  Most screening evaluations must be no more than 28 days prior to Day 0 to be used for eligibility (pregnancy test on Day 0 must be used for eligibility) . If clinical assessment on   
Day 0 suggests significant changes may have occurred since screening, then physical examination and laboratory studies done on Day 0 are used for eligibility.   
1 Day 0=day of randomization  and first  product administration. Day 0 evaluations prior to first product administration  are the baseline for assessing adverse events subsequently.  
2 Screening visit includes a physical exam with vital signs. At other visits a physical examination is done if indicated by int erim history or laboratory test results. Otherwise only 
blood press ure (BP), pulse, and temperature are required.  
3 Study product administration s: Complete post vaccination evaluations (BP, pulse, temperature, respiration and product administration site assessment) at 30 minutes or longer after 
each product administration .  Subjects who receive only one product administration are expected to continue with follow -up through study Week 36.  
4 Negative pregnancy test results must be confirmed for women of reproductive potential prior to product administration s. 
Visit Windows : Schedule Visits 02A through 05 with respect to Day 0; Schedule Visits 05A through 9 with respect to Visit 05.  
The following visit windows apply: Visits 02A and 05A (+1 day). Visit s 03 and 06 (±3 day). Visits 04 and 07 (±7 days). Visit 05 (± 7 days). Visi ts 08 and 09 (±14 days).  
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 60 of 66  
 APPENDIX IV: ASSESSMENT OF RELATIONSHIP TO VACCINE  
AND  
GRADING SEVERITY OF ADVERSE EVENTS  
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 61 of 66 Assessment of Causality Relationship of an Adverse Event to Study Vaccine:  
The relationship between an adverse event (AE) and the vaccine will be assessed by the 
investigator on the basis of his or her clinical judgment and the definitions below. 
Definite ly Related . The AE and administration of study agent are related in time, and a 
direct association can be demonstrated.  
Probably Related . The AE and administration of study agent are reasonably related in 
time, and the AE is more likely explained by study agent than other causes.  
Possibly Related . The AE and administration of study agent are reasonably related in 
time, but the AE can be explained equally well by causes other than study agent. 
Not Related . There is not a reasonable possibility that the AE is related to the study 
agent.  
For purposes of preparing data reports in which AE attributions are limited to “ Related ” or “Not 
Related ”, in this protocol, the “Definitely, Probably and Possibly” attributions  will be  mapped 
to the “Related” category.  The definitions that apply when these two categories alone are used are as follows:  
Related  – There is a reasonable possibility that the AE may be related to the study agent.  
Not Related  – There is not a r easonable possibility that the AE is related to the study 
agent.  
Grading the Severity of Adverse Events:  
The FDA Guidance for Industry (September 2007): “Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials” is the basis for the severity grading of AEs in this protocol. Several modifications were made to the table as follows: 
“Emergency room visit” is not automatically considered a life -threatening event; these 
words have been removed from any “grade 4’ definition where they appear in the 
table copied from the guidance document. 
Any laboratory value shown as a “graded” value in the table that is within the 
institutional normal range will not be severity graded or recorded as an AE. 
Severity grading  for hemoglobin decrease on the basis of the magnitude of decrease from 
baseline is not applicable at the grade 1 level; only absolute hemoglobin will be used to define grade 1 decrease.  Increases in hemoglobin are AEs only for values above the upper limi t of normal and are graded by the systemic illness clinical criteria.  
Severity grading definition for Grade 4 local reaction to injectable product 
(Erythema/Redness and Induration/Swelling) included added text “requiring medical attention”.  
1 X ULN was rem oved from the definition for PT increase. 
 
When not otherwise specified in the table, the following guidance will be used to assign a 
severity grade:  
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 62 of 66 Grade 1 (Mild):  No effect on activities of daily living  
Grade 2 (Moderate):  Some interference with activi ty not requiring medical intervention  
Grade 3 (Severe):  Prevents daily activity and requires medical intervention  
Grade 4 (Life- threatening):  Hospitalization; immediate medical intervention or therapy  
required to prevent death. 
Grade 5 (Death):   Death is assigned a Grade 5 severity.  
Only the single AE that is assessed as the primary cause of death should be assigned “grade 5” 
severity.   
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 63 of 66 Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in 
Preventive Vaccine Clinical Trials  
FDA Guidance   -  September 2007  
 
A. Tables for Clinical Abnormalities  
Local Reaction to  
Injectable Product  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe 
(Grade 3)  Potentially Life  
Threatening  
(Grade 4)  
Pain  Does not interfere  
with activity  Repeated use of 
non-narcotic pain 
reliever > 24 hours 
or interferes with 
activity  Any use of narcotic 
pain reliever or prevents daily  
activity  Hospitalization  
Tenderness  Mild discomfort to 
touch  Discomfort with 
movement  Significant  
discomfort at rest  Hospitalization  
1Erythema/Redness   2.5 – 5 cm  5.1 – 10 cm  > 10 cm  Necrosis or  
exfoliative dermatitis requiring 
medical attention  
2 Induration/Swelling   2.5 – 5 cm and does 
not interfere  
with activity  5.1 – 10 cm or  
interferes with  
activity  > 10 cm or  
prevents daily  
activity  Necrosis requiring 
medical attention  
 
3 Vital Signs  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe 
(Grade 3)  Potentially Life  
Threatening  
(Grade 4)  
4 Fever (°C)  
           (°F)  38.0 – 38.4  
100.4 – 101.1  38.5 – 38.9  
101.2 – 102.0  39.0 – 40  
102.1 – 104  > 40  
> 104  
Tachycardia - beats per  
minute  101 – 115  116 – 130  > 130  Hospitalization for  
arrhythmia  
5 Bradycardia - beats per  
Minute  50 – 54  45 – 49  < 45  Hospitalization for  
arrhythmia  
Hypertension (systolic) -  
mm Hg  141 – 150  151 – 155  > 155  Hospitalization for  
malignant  
hypertension  
Hypertension (diastolic) -  
mm Hg  91 – 95  96 – 100  > 100  Hospitalization for  
malignant  
hypertension  
Hypotension (systolic) –  
mm Hg  85 – 89  80 – 84  < 80  Hospitalization for  
hypotensive shock  
Respiratory Rate – breaths  
per minute  17 – 20  21 – 25  > 25  Intubation  
 
1. In addition to grading the measured local reaction at the greatest single diameter, the measurement should be recorded as 
a continuous variable.  
2. Induration/Swelling should be evaluated and graded using the functional scale as well as the actual measuremen t. 
3. Subject should be at rest for all vital sign measurements.  
4. Oral temperature; no recent hot or cold beverages or smoking.  
5. When resting heart rate is between 60 – 100 beats per minute. Use clinical judgment when characterizing  
Bradycardia among some healthy subject populations, for example, conditioned athletes.  
 
 
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 64 of 66  
Systemic (General)  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe 
(Grade 3)  Potentially Life  
Threatening  
(Grade 4)  
Nausea/vomiting  No interference  
with activity or 1 – 
2 
episodes/24 hours  Some interference  
with activity or > 2  
episodes/24 hours  Prevents daily  
activity, requires  
outpatient IV  
hydration  Hospitalization for  
hypotensive shock  
Diarrhea  2 – 3 loose stools or  
< 400 gms/24 hours  4 – 5 stools or  
400 – 800 gms/24  
hours  6 or more watery  
stools or  > 800gms/24 hours  
or requires  outpatient IV  
hydration  Hospitalization  
Headache  No interference 
with 
activity  Repeated use of 
non-  
narcotic pain  
reliever > 24 hours or 
some interference  
with activity  Significant; any  
use of narcotic  pain reliever or  
prevents daily  
activity  Hospitalization  
Fatigue  No interference 
with 
activity  Some interference  
with activity  Significant;  
prevents daily  
activity  Hospitalization  
Myalgia  No interference 
with 
activity  Some interference  
with activity  Significant;  
prevents daily  
activity  Hospitalization  
 
Systemic Illness  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
 (Grade 3)  Potentially Life  
Threatening  
(Grade 4)  
Illness or clinical adverse  
event (as defined  according to applicable  
regulations)  No interference with  
activity  Some interference  
with activity not  
requiring medical  
intervention  Prevents daily  
activity  and  
requires medical  
intervention  Hospitalization  
 
B. Tables for Laboratory Abnormalities  
 
The laboratory values provided in the tables below serve as guidelines and are dependent upon 
institutional normal parameters.  Institutional normal reference ranges should be provided to demonstrate that they are appropriate. 
 
Serum*  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe 
(Grade 3)  Potentially Life  
Threatening  
(Grade 4)**  
Sodium – Hyponatremia 
mEq/L  132 – 134  130 – 131  125 – 129  < 125  
Sodium – Hypernatremia 
mEq/L  144 – 145  146 – 147  148 – 150  > 150  
Potassium – 
Hyperkalemia mEq/L  5.1 – 5.2  5.3 – 5.4  5.5 – 5.6  > 5.6  
P R O D U C T: V R C -W E V V L P 0 7 3 -0 0 -V P   
P R O T O C O L V R C 3 1 3, V E R SI O N 1. 0  P R O T O C O L D A T E: J A N U A R Y 9 , 2 0 1 9  
 
P a ge 6 5  of 6 6  Ser u m *  Mil d  
( Gr a de 1)  M o der ate  
( Gr a de 2)  Se vere  
( Gr a de 3)  P ote nti all y Life  
T hre ate ni n g  
( Gr a de 4) * *  
P otassi u m – H y p o kale mia 
m E q/ L  3. 5 – 3. 6  3. 3 – 3. 4  3. 1 – 3. 2  < 3. 1  
Gl uc ose – H y p o gl yce mia 
m g/ d L  6 5 – 6 9  5 5 – 6 4  4 5 – 5 4  < 4 5  
Gl uc ose – H y per gl yce mia  
Fasti n g – m g/ d L  
Ra n d o m – m g/ d L  1 0 0 – 1 1 0  
1 1 0 – 1 2 5  1 1 1 – 1 2 5  
1 2 6 – 2 0 0  > 1 2 5  
> 2 0 0  I ns uli n 
re q uire me nts or 
h y per os m olar c o ma  
Bl o o d Urea Nitr o ge n  
B U N m g/ d L  2 3 – 2 6  2 7 – 3 1  > 3 1  Re q uires dial ysis  
Creati ni ne – m g/ d L  1. 5 – 1. 7  1. 8 – 2. 0  2. 1 – 2. 5  > 2. 5 or re q uires 
dial ysis  
Calci u m – h y p ocalce mia 
m g/ d L  8. 0 – 8. 4  7. 5 – 7. 9  7. 0 – 7. 4  < 7. 0  
Calci u m – h y percalce mia 
m g/ d L  1 0. 5 – 1 1. 0  1 1. 1 – 1 1. 5  1 1. 6 – 1 2. 0  > 1 2. 0  
Ma g nesi u m – 
h y p o ma g nese mia m g/ d L  1. 3 – 1. 5  1. 1 – 1. 2  0. 9 – 1. 0  < 0. 9  
P h os p h or o us – 
h y p o p h os p hate mia m g/ d L  2. 3 – 2. 5  2. 0 – 2. 2  1. 6 – 1. 9  < 1. 6  
C P K – m g/ d L  1. 2 5 – 1. 5 x 
U L N * * *  1. 6 – 3. 0 x U L N  3. 1 –1 0 x U L N  > 1 0 x U L N  
Al b u mi n – 
H y p oal b u mi ne mia g/ d L  2. 8 – 3. 1  2. 5 – 2. 7  < 2. 5  --   
T otal Pr otei n – 
H y p o pr otei ne mia g/ d L  5. 5 – 6. 0  5. 0 – 5. 4  < 5. 0  --   
Al kali ne p h os p hate –  
i ncrease b y fact or  1. 1 – 2. 0 x U L N  2. 1 – 3. 0 x U L N  3. 1 – 1 0 x U L N  > 1 0 x U L N  
Li ver F u ncti o n T ests –
A L T, A S T  
i ncrease b y fact or  1. 1 – 2. 5 x U L N  2. 6 – 5. 0 x U L N  5. 1 – 1 0 x U L N  > 1 0 x U L N  
Bilir u bi n – w he n 
acc o m pa nie d  
b y a n y i ncrease i n Li ver 
F u ncti o n T est  
i ncrease b y fact or  1. 1 – 1. 2 5 x U L N  1. 2 6 – 1. 5 x U L N  1. 5 1 – 1. 7 5 x U L N  > 1. 7 5 x U L N  
Bilir u bi n – w he n Li ver 
F u ncti o n T est is n or mal; 
i ncrease b y fact or  1. 1 – 1. 5 x U L N  1. 6 – 2. 0 x U L N  2. 0 – 3. 0 x U L N  > 3. 0 x U L N  
C h olester ol  2 0 1 – 2 1 0  2 1 1 – 2 2 5  > 2 2 6  ---   
P a ncreatic e nz y mes – 
a m ylase, li pase  1. 1 – 1. 5 x U L N  1. 6 – 2. 0 x U L N  2. 1 – 5. 0 x U L N  > 5. 0 x U L N  
* T he la b orat or y val ues pr o vi de d i n t he ta bles ser ve as g ui d eli nes a n d are de pe n de nt u p o n i nstit uti o nal n or mal 
para meters. I nstit uti o nal n or mal refere nce ra n ges s h o ul d be pr o vi de d t o de m o nstrate t hat t he y are  a p pr o priate.  
* * T he cli nical si g ns or s y m pt o ms ass ociate d wit h la b orat or y a b n or malities mi g ht res ult i n c haracterizati o n of 
t he la b orat or y a b n or malities as P ote ntiall y Life T hreate ni n g ( Gra de 4). F or e xa m ple, a l o w s o di u m val ue t hat 
falls wit hi n a gra de 3 para met er ( 1 2 5 -1 2 9 m E/ L) s h o ul d be rec or de d as a gra de 4 h y p o natre mia e ve nt if t he 
s u bj ect ha d a ne w seiz ure ass o ciate d wit h t he l o w s o di u m val ue.  
* * * U L N” is t he u p per li mit of t he n or mal ra n ge.  
 
 
 
PRODUCT: VRC -WEVVLP073-00 -VP  
PROTOCOL VRC 313, VERSION 1.0  PROTOCOL DATE: JANUARY 9 , 2019  
 
Page 66 of 66  
Hematology*  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  Potentially Life  
Threatening 
(Grade 4)  
Hemoglobin (Female) - 
gm/dL  11.0 – 12.0  9.5 – 10.9  8.0 – 9.4  < 8.0  
Hemoglobin (Female)  
decrease from baseline 
value - gm/dL  not applicable  1.6 – 2.0  2.1 – 5.0  > 5.0  
Hemoglobin (Male) - 
gm/dL  12.5 – 13.5  10.5 – 12.4  8.5 – 10.4  < 8.5  
Hemoglobin (Male)  
decrease from baseline 
value – gm/dL  not applicable  1.6 – 2.0  2.1 – 5.0  > 5.0  
WBC Increase - cell/mm3 10,800 – 15,000  15,001 – 20,000  20,001 – 25, 000  > 25,000  
WBC Decrease - cell/mm3 2,500 – 3,500  1,500 – 2,499  1,000 – 1,499  < 1,000  
Lymphocytes Decrease - 
cell/mm3 750 – 1,000  500 – 749  250 – 499  < 250  
Neutrophils Decrease - 
cell/mm3 1,500 – 2,000  1,000 – 1,499  500 – 999  < 500  
Eosinophils - cell/mm3 650 – 1500  1501 - 5000  > 5000  Hypereosinophilic  
Platelets Decreased - 
cell/mm3 125,000 – 140,000  100,000 – 124,000  25,000 – 99,000  < 25,000  
PT – increase by factor  
(prothrombin time)  1.10 x ULN**  1.11 – 1.20 x ULN  1.21 – 1.25 x ULN  > 1.25 ULN  
PTT – increase by factor  
(partial thromboplastin 
time)  1.10 – 1.20 x ULN  1.21 – 1.4 x ULN  1.41 – 1.5 x ULN  > 1.5 x ULN  
Fibrinogen increase - 
mg/dL  400 – 500  501 – 600  > 600  --  
Fibrinogen decrease - 
mg/dL  150 – 200  125 – 149  100 – 124  < 100 or associated  
with gross bleeding  
or disseminated 
intravascular 
coagulation (DIC)  
* The laboratory values provided in the tables serve as guidelines and are dependent upon institutional normal parameters. Institutional normal reference ranges should be provided to demonstrate that they are appropriate.
 
 
    
 
 
Date:               March 12, 2019 RE: Letter of Amendment #1  
Protocol VRC 31 3, Version 1.0 (January 9, 2019) 
To:  Emory University Institutional Review Board  
From:   Srilatha Edupuganti, M.D. , MPH,  Principal Investigator   
 
             
Letter of Amendment # 1 
 
This Letter of Amendment (L oA) affects the VRC 31 3, Version 1.0 (January 9, 2019). This letter 
and any IRB correspondence pertaining to this letter will be filed in the protocol regulatory file and other pertinent files.   
Purpose of the Letter of Amendment   
The purpose of this LoA is to update the protocol as described below. New text is shown in bold, 
deleted text in  strikethrough.  
 1. Title  page 
Correct a typo in the IND number as follows: BB-IND 1173817338  
 
2. Section 4.1, Inclusion Criteria  
Clarify inclusion citerion #9 as follows: “White blood cell (WBC) and  differential either within 
institutional normal range or accompanied by PI or designee approval”  3. Section 4.2.2, Screening  
Since a witness signature on the ICF is not required, the following text  is to be modified as 
follows: “Before screening procedures can be performed, informed consent must be obtained, and the form must be signed, dated and timed by the subject as well as signed and dated by the consenter and a witness. Any member of the research/clinical team can be a witness, but a 
consenter and a witness should not be the same person at the same time.” 
 
4. Section 4.2, Clinical Procedures and Evaluations 
Add a new sub- section “ Birth Control ” to clarify that: 
• Adequate methods of reversible/temporary birth control  for women generally include: 
abstinence; condoms, male or female, with or without a spermicide; diaphragm or cervical 
cap with spermicide; intrauterine devices and other prescription methods (such as contraceptive pills, hormone implants, injections, patches and others); or a male partner 
who has previously undergone a vasectomy. 
 
• Permanent birth control for women  include s: 
 
- Hysterectomy or partial hysterectomy are both forms of permanent birth control 
- Tubal ligation or Essure implant:  FDA has prevented sales of Essure in the U.S. since 
Dec. 2018, but health care providers may continue to implant current devices for 1 year 
from date of purchase if they review the black box warning and “Patient -Doctor 
Discussion Checklist” with  the patient.  

− M
enopausal (menses ceased for at least 1 year and no other biological or physiological 
cause in medical history)  
Women who have permanent birth control do not need pregnancy testing .  
 
5. A
ppendix I,  Study Informed Consent Form Template  
- U
nder “Study Plan” clarify that the length of the study is 9 months as follows: “ You 
will be in the study for about 36 weeks (8 9 months) and have about 9 clinic visits and 
2 t
elephone contacts.”  
- R
emove the signature line for witness    
 
6.  Appendix II, Contact Information 
-  
 
  
  
 
 
7. Appendix I II, Schedule of Evaluations   
- Clarify that HIV testing will be done per institutional guidelines by HIV antibody (Ab)/antigen (Ag) combination assay using 5 ml of  blood  
- The Schedule of Evaluations with updated blood Daily Volume and Max. Cumulative 
Volume (blood volumes increased  by 1 m L) is attached  
 
No changes to the to the study conduct, subject’s risks and to content of the informed consent are 
indicated based on this LoA. 
The changes described herein will be incorporated into the next version of protocol VRC 313 if amended  in the future. 
Also with this LoA, we submit for approval a modified Assessment of Understanding (AoU) to which we added a line to indicate the time when the AoU was conducted . 

 
. 
D
ate:               April 2 3, 2019 
RE: Letter of Amendment #2  
Protocol VRC 31 3, Version 1.0 (January 9, 2019) 
To:  Emory University Institutional Review Board  
From:   Srilatha Edupuganti, M.D. , MPH,  Principal Investigator   
 
             
L
etter of Amendment # 2 
 
This Letter of Amendment (L oA) affects the VRC 31 3, Version 1.0 (January 9, 2019). This letter 
and any IRB correspondence pertaining to this letter will be filed in the protocol regulatory file and other pertinent files.   
P
urpose of the Letter of Amendment   
T
he purpose of this LoA is to update the protocol as described below.  
 1. Cover page  
- U
nder “Protocol Chairs ”:  
o Add G
race Chen, M.D., M.P.H. 
o Remove Cristina A. Carter, M.D.  
 2.  Appendix II, Contact Information:  
-   
  
    
 
  
  
  
  
  
  
 
  
   
  
 
N
o changes to the study conduct , subject’s risks and to content of the informed consent are 
indicated based on this LoA. 
The changes described herein will be incorporated into the next version of protocol VRC 313 if 
amended  in the future. 

 
. 
Date:               October 24, 2019 
RE: Letter of Amendment #3  
Protocol VRC 31 3, Version 1.0 (January 9, 2019) 
To:  Emory University Institutional Review Board  
From:   Srilatha Edupuganti, M.D. , MPH,  Principal Investigator   
 
             
Letter of Amendment # 3 
 
This Letter of Amendment (L oA) affects the VRC 31 3, Version 1.0 (January 9, 2019). This letter 
and any IRB correspondence pertaining to this letter will be filed in the protocol regulatory file and other pertinent files.   
Purpose of the Letter of Amendment   
The purpose of this LoA is to update the protocol as described below. New text is shown in bold 
in the “in the “ Schedule of Evaluations ”.” 
 
1. “Appendix III: Schedule of Evaluations ” 
 
o Add collection of PBMC and plasma for exploratory immunogenicity evaluations at either Visit 08 or Visit 09 for all subjects enrolled in Groups 3-6 that have not yet completed Visit 08 or 09   
o Update the collection of blood and volume at Visits 8 or Visit 9 from 1 6mL SST 
tube to: 
• 8 ml for a ntibody assays and serum  in SST tube 
• 8 ml for PBMC and plasma in CPT tube  
o No extra blood will be collected for any subjec t at Visits 8 or Visit 9, and the 
daily volume and max. cumulative volume remains the same. 
 
 
No changes to the study conduct , subject’s risks and to content of the informed consent are 
indicated based on this LoA. 
The changes described herein will be incorporated into the next version of protocol VRC 313 if 
amended  in the future. 

 
 Screen  VRC 313 Schedule of Evaluations  
Visit  *01 02 02A 03 04 05 05A 06 07 08 09 
Week of Study  -4 to 0  W1 W1 W2 W4 W8 W9 W10  W12  W24  W36  
Day of Study  -28 to 0  D01 D2 D14 D28 D56 D58 D70 D84 D168  D252  
Clinical  Tube             
VRC 313 Inf ormed Consent   X           
VRC 313 AoU   X           
2 Physical exam  for eligibility, height /weight /vital signs and 
targeted exam (as needed) at other visits.   X X  X X X  X  X  X  X  
Medical history targeted to eligibility at screening; then 
interim medical history   X X  X X X  X  X  X  X  
3Study product administration    X    X      
Phone evaluation (clinic visit as needed)     X    X     
Begin 7 -Day Diary Card    X    X      
4Pregnancy test: urine (or serum)   X X    X    X  
Counseling on pregnancy prevention/  Reproductive 
Information Form   X X  X  X  X  X  X  X X 
CBC, differential, platelet count  EDTA  3 3  3 3 3  3 3 3 3 
ALT SST 4 4  4 4 4  4 4 4 4 
Creatinine  SST X X    X      
HIV ELISA (Western blot or PCR, if needed)  SST 4           
Research              
Antibody as says and serum  SST *16 32  16 32 32  16 32 16 [8]5 16 [8]5 
5PBMC and plasma   CPT                [8]5      [8]5 
Daily Volume (mL)   27 39 0 23 39 39 0 23 39 23 23 
Max. Cumula tive Volume (mL)   27 66 66 89 128 167 167 190 229 252 275 
* Screening :  Most screening evaluations must be no more than 28 days prior to Day 0 to be used for eligibility (pregnancy test on Day 0 must be used 
for eligibility). If clinical assessment on   Day 0 suggests significant changes may have occurred since screening, t hen physical examination and 
laboratory studies done on Day 0 are used for eligibility.   
1 Day 0=day of randomization and first product administration. Day 0 evaluations prior to first product administration are the baseline for assessing 
adverse events s ubsequently.  
2 Screening visit includes a physical exam with vital signs. At other visits a physical examination is done if indicated by interim history or laboratory 
test results. Otherwise only blood pressure (BP), pulse, and temperature are required. 
3 Study product administrations: Complete post vaccination evaluations (BP, pulse, temperature, respiration and product administration site assessment) 
at 30 minutes or longer after each product administration.  Subjects who receive only one product administration are expected to continue with follow-
up through study Week 36.  
4 Negative pregnancy test results must be confirmed for women of reproductive potential prior to product administrations. 
Visit Windows : Schedule Visits 02A through 05 with respect to Day 0; Schedule Visits 05A through 9 with respect to Visit 05.  
The following visit windows apply: Visits 02A and 05A (+1 day). Visits 03 and 06 (±3 day). Visits 04 and 07 (±7 days). Visit 05 (± 7 days). Visits 08 and 09 (±14 days). 
5PBMC and plasma collection  for all subjects enrolled in Groups 3 -6 that have not yet completed Visit 08 or Visit 09.  
ONLY draw 8 mL in SST (DO NOT draw 1 6 ml in SST  tubes  IF collecting PBMC and plasma ). 
Study No.: IRB00108969  Emory University IRB  
IRB use only  Document Approved On: 3/18/2019  
 
 
 
VRC 313; Protocol V1 dated 09Jan2019                           Page 1 of 12                                                    ICF Vers ion: 2 Date: 03/12/2019 
PI: Srilatha Edupuganti, MD                                                                                                                                          IRB Form 12142018   
You Are Being Asked to Be in a Research Study 
Concise presentation of key concepts 
 
You are being asked to be in a research study. A research study is designed to answer a scientific question. If 
you agree and are eligible to be in the study, you will be one of up to 40 people who are participating in this 
study at Emory.  
 
Why is this study being done?  
This study is being done to answer the questions: Is the WEVEE vaccine safe and tolerable to give people? Is 
it safe and tolerable at all three different dose levels? Is it safe and tolerable both with and without adding 
aluminum hydroxide (alum) to the vaccine? You are being asked to be in this research study because you are 
between the ages of 18 and 50 and are in generally good health.   
 
Do you have to be in the study?  
It is your decision to be part of this research study. You do not have to be in it. Before you make your decision, 
you should take time to learn about the study. 
 
What do I have to do if I choose to participate in this study? 
If you are eligible and want to participate in the study, you will participate for 9 months (9 study visits).  The 
researchers will ask you to do the following : receive 2 vaccinations, provide information about your medical 
history, current medications and current health, have blood samples drawn and keep a symptom diary after 
each injection.  ALL study procedures will be paid for by the study.    
 
Is this study going to help you?  
This study is not designed to benefit you directly. If you are in the study, you will be helping the researchers 
answer the study questions .  
 
What are the risks or discomforts I should know about before making a decision?   
The study will take time. The vaccine that is being tested may not work and may even cause harm. All studies 
have some risks.  Some risks are relatively small, like being bored or losing time.  Some are more serious – for 
this study, these include irritation at the injection site, allergic reaction, flu-like symptoms, loss of privacy, and 
breach of confidentiality.  A fu ll list of expected risks, their frequency and severity are in the “What are the 
possible risks and discomforts?” section of this document.  
 
Alternatives to Joining This Study 
You may choose not to participate in this study. If you do choose to participate, you may change your mind and 
withdraw from the study at any time. 
 
Costs 
You WILL NOT have to pay for any of the study procedures. 
 
What Should I Do Next? 
Read this form or have it read to you.  Make sure the study doctor or study staff explains the study to you. Ask 
questions (e.g., about exact time commitment, about unfamiliar words, more details on specific procedures, 
etc.) Make sure you understand . Take time to consider this and talk about it with your family and friends. 
 
Study No.: IRB00108969  Emory University IRB  
IRB use only  Document Approved On: 3/18/2019  
 
 
 
VRC 313; Protocol V1 dated 09Jan2019                           Page 2 of 12                                                    ICF Vers ion: 2 Date: 03/12/2019 
PI: Srilatha Edupuganti, MD                                                                                                                                          IRB Form 12142018 Emory University 
Consent to be a Research Subject 
 
Title: A Phase 1 Open Label, Dose-Escalation Clinical Trial to Evaluate the Safety and Immunogenicity of a 
Trivalent Virus-Like Particle (VLP) Encephalitis Vaccine, VRC WEVVLP073- 00-VP, in Healthy Adults 
 
Principal Investigator:  Srilatha Edupuganti, MD, MPH  
 
Sponsor : The Vaccine Research Center (VRC) and the National Institute of Allergy and Infectious Disease 
(NIAI D) 
 
Introduction 
You are being asked to be in a medical research study. This form is designed to tell you everything you need 
to think about before you decide if you want to be a part of the study.  It is entirely your choice.  If you 
decide to take part, you can change your mind later on and withdraw from the research study.  The 
decision to join or not join the research study will not cause you to lose any medical benefits.  If you decide not 
to take part in this study, you can still receive medical care at Emory. 
 
Before making your decision: 
 Please carefully read this form or have it read to you 
 Please listen to the study doctor or study staff explain the study to you  
 Please ask questions about anything that is not clear 
 
You can take a copy of this consent form, to keep. Feel free to take your time thinking about whether you 
would like to participate. You may wish to discuss your decision with family or friends. Do not sign this consent 
form unless you have had a chance to ask questions and get answers that make sense to you.  By signing this 
form, you will not give up any legal rights. 
 
A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required by U.S. law. This 
Web site will not include information that can identify you. At most the Web site will include a summary of the 
study  results. You can search this Web site at any time. 
 
What is the purpose of this study? 
The purpose of this study is to test an experimental vaccine against viral encephalitis. This is the first study in 
people of this experimental vaccine for the prevention of Western equine encephalitis virus, Eastern equine 
encephalitis virus, and Venezuelan equine encephalitis virus infection.  The word “Encephalitis” means 
swelling of the brain, which occurs in some people who get infected by these viruses.  “Experimental” means 
that the Food and Drug Administration (FDA) has not approved this study vaccine for general use in the public.  
The FDA allows it to be used for research only.  We do not know if this vaccine works.  The main purpose of 
this study is to see if the experimental vaccine is safe and if there are any side effects.  We also want to study 
the immune response to this vaccine. 
 
Western, Eastern and Venezuelan equine encephalitis viruses are very similar to each other and cause a 
similar type of disease in humans. These 3 viruses were first seen in horses; that’s why they were named 
“equine”.  The viruses are passed to humans by mosquitoes.  Infection from these viruses can cause fever, 
chills, discomfort, feeling sick, muscle pain and then headache, vomiting, restlessness, irritability, seizures, 
coma, and death. There are no viruses in the vaccine, and therefore you can’t get infected by the vaccine. 
 
We expect that 30-40 people will receive a vaccine on this study. In order to find enough people, we may 
screen up to 120 people .  
 
Study No.: IRB00108969  Emory University IRB  
IRB use only  Document Approved On: 3/18/2019  
 
 
 
VRC 313; Protocol V1 dated 09Jan2019                           Page 3 of 12                                                    ICF Vers ion: 2 Date: 03/12/2019 
PI: Srilatha Edupuganti, MD                                                                                                                                          IRB Form 12142018  
What is the vaccine being used in this study? 
Vaccines are given to teach the body to prevent or fight an infection.  In this study, we are testing an 
experimental vaccine that was developed by the Vaccine Research Center (VRC) at the National Institutes of 
Health (NIH). It is named VRC-WEVVLP073- 00-VP; it is also called the “WEVEE” vaccine.   This vaccine is 
intended to help the body to make an immune response to Western, Eastern and Venezuelan equine 
encephalitis viruses. 
 
The WEVEE vaccine: Most vaccines are made of proteins that are injected into a muscle. Proteins are natural 
substances that the body and viruses use as building blocks. The WEVEE vaccine is a type of vaccine known 
as a virus-like particle (VLP) vaccine. This is because it is made up of proteins from the Western, Eastern and 
Venezuelan equine encephalitis viruses that make particles looking like the outside surface of these 3 viruses. 
The body’s immune system may respond to these particles by making cells to fight off these viruses.  
 
However, there are no live or killed viruses in the vaccine, so you cannot get infected with any of these 3 
viruses from getting the vaccine.  This is the first study to give the WEVEE vaccine to humans. This 
experimental vaccine may or may not protect you from Western, Eastern and Venezuelan equine encephalitis 
viruses’  infection. 
 
Some people in this study will get the WEVEE vaccine mixed with another study product called an adjuvant. 
Adjuvants are substances that may make your body’s response to the vaccine better.  The adjuvant in this 
study will be aluminum hydroxide (alum).  Alum has been used for over 60 years in billions of vaccinations with 
licensed vaccines and has been found to be safe.  The use of alum as an adjuvant in this study has been 
reviewed and approved by the FDA. 
 
Who can take part in this study?  
You may be eligible to take part in this study if you are: 
 between 18 and 50 years of age 
 in general good health without significant medical problems  
 willing to get the WEVEE vaccine 
 willing to give blood samples for future research  
 Additionally, if you are a female who is able to become pregnant: willing to use birth control from at 
least 21 days before randomization through the end of the study 
 
What will I be asked to do? 
 
Screening  
Before you can take part in this experimental study, your health will be checked so we can decide if you qualify 
to participate.  You will need to sign this consent form before screening.  If you qualify, then you may take part 
in the vaccine study. 
 
Screening includes a physical exam and blood tests to check your health, including for HIV.  We will ask you 
about your health history.  If you are a female who is able to have children, you will be asked about the 
possibility of you becoming pregnant while in the study.  You will be tested for pregnancy either by collecting 
your urine or blood.  During screening, we will collect some blood to store for research.  We will review the test 
results with you and tell you if the results show that you are eligible to join the study.   
 
Study Procedures 
About 30 to 40 people will take part in this study.  You will be in the study for about 36 weeks (9 months) and 
have about 9 clinic visits and 2 telephone contacts.  You will get 2 vaccinations, each by injection (shot) in the 
upper arm muscle.  This is c alled an intramuscular “IM” injection.  We will check you for any side effects from 
Study No.: IRB00108969  Emory University IRB  
IRB use only  Document Approved On: 3/18/2019  
 
 
 
VRC 313; Protocol V1 dated 09Jan2019                           Page 4 of 12                                                    ICF Vers ion: 2 Date: 03/12/2019 
PI: Srilatha Edupuganti, MD                                                                                                                                          IRB Form 12142018 the vaccine.   
 
We will tell you if we learn anything new during this study that might cause you to change your mind about 
staying in the study.  At the end of the study, we will tell you when study results may be available and how to 
learn about them. 
 
If you agree to take part in the study, you will be randomly assigned (like pulling a number from a hat) to get 
either: 
 The WEVEE vaccine alone (Group 1, Group 3, and Group 5) or,  
 The WEVEE vaccine mixed with alum (Group 2, Group 4, and Group 6).  
 
Once enrolled, you will know which group you are in.  
 
The study will start by randomizing people to get a dose of 6 mcg in Group 1 or Group 2.  We will review the 
data after about 2 weeks to make sure this vaccine dose has no safety concerns before we start randomizing 
people to get the next dose of 30 mcg in Group 3 or Group 4. We will review the data for this dose after about 
2 weeks to make sure this vaccine dose has no safety concerns before we start randomizing people to the 60 
mcg dose in Group 5 or Group 6. 
 
The table below shows the vaccination plan: 
 
VRC 313  
Group  Subjects  Dose  Day 0  Week 8  
1 5 6 mcg  WEVEE  WEVEE  
2 5 WEVEE + alum  WEVEE + alum  
3 5 30 mcg  WEVEE  WEVEE  
4 5 WEVEE + alum  WEVEE + alum  
5 5 60 mcg  WEVEE  WEVEE  
6 5 WEVEE + alum  WEVEE + alum  
Total  30 *Up to 10 more people may be enrolled if needed.  
 
Each vaccination visit will take about 2 to 3 hours.  Other clinic visits will take about 1 to 2 hours.  The clinic 
staff will watch you for at least 30 minutes after each vaccination.   
 
Timepoint  Type of Visit  Duration  
Day 0  Enrollment/Vaccination  2 to 3 hours  
Day 2  Phone call  15 minutes  
Week 2  Follow up clinic visit  1 to 2 hours  
Week 4  Follow up clinic visi t 1 to 2 hours  
Week 8  Second vaccination  2 to 3 hours  
Week 9  Phone call  15 minutes  
Week 10  Follow up clinic visit  1 to 2 hours  
Week 12  Follow up clinic visit  1 to 2 hours  
Week 24  Follow up clinic visit  1 to 2 hours  
Week 36  Follow up clinic visit  1 to 2 hours  
 
If you are a woman who is able to get pregnant, we will do a pregnancy test before each injection.  The test 
must show that you are not pregnant to get the injection. We may collect urine from you to perform this test. 
 
You will have a telephone call about 2 days after each vaccination so we can check on you.   
Study No.: IRB00108969  Emory University IRB  
IRB use only  Document Approved On: 3/18/2019  
 
 
 
VRC 313; Protocol V1 dated 09Jan2019                           Page 5 of 12                                                    ICF Vers ion: 2 Date: 03/12/2019 
PI: Srilatha Edupuganti, MD                                                                                                                                          IRB Form 12142018  
You will need to complete a diary card at home for 7 days after each vaccination.  The purpose of the diary 
card is so you can write down any symptoms that the vaccine may cause.  We will ask you to record your 
temperature daily and look at the injection site on your arm each day.  We will give you a thermometer to 
measure your temperature and a ruler to measure any skin changes at the injection site.  You will get a 
password to a secure website to enter this data online.  If you do not have access to the internet, you may use 
a paper diary card instead. 
 
If you have any side effects, you should tell a clinic nurse or doctor as soon as possible.  You can reach the 
staff by phone 24 hours a day.  If you have symptoms, you may be asked to come to the clinic for an 
examination before your next scheduled visit.  With your consent, we may take a photograph of any reactions 
you have to the vaccine.  It is very important that you follow the instructions from the clinic staff. 
 
At each visit, we will check you for any health changes or problems.  We will ask you how you are feeling and if 
you have taken any new medications.  We will draw your blood at each visit, taking up to 5 tubes of blood.  We 
will tell you right away if any of your test results show a health problem.  Some blood samples will be used for 
research only, to study your immune response to the vaccine.  Results of these research tests are not used to 
check your health and will not be given to you. 
 
Who owns my study information and samples? 
If you join this study, you will be donating your samples and study information.   You will not receive any 
compensation if your samples or information are used to make a new product. If you withdraw from the study, 
data and samples that were already collected may be still be used for this study.   
 
Stored Samples 
Some of the blood we draw from you during the study will be used by investigators to study proteins and other 
molecules that may be involved in the immune response. Blood samples will be stored for future research to 
learn more about WEVEE, vaccines, the immune system, and/or other medical conditions. 
 
The results from the research done with your stored samples are not meant to be used for medical care.  They 
will not be given to your health care provider and will not be put in your medical record.  
 
You may not take part in this study if you are not willing to have your blood samples stored for future 
analysis. 
 
Labeling of Stored Samples :  Your stored samples will be labeled by a special code or number and not your 
personal information.  Only the study team can link this code to you.  Any identifying information about you (like 
name or date of birth) will be kept as confidential as allowable by law. 
 
Risks from Stored Samples:   There is a risk of unplanned release of information from your medical records.  
The chance that this information will be given to an unauthorized person without your permission is very small.  
Possible problems with the unplanned release of information include discrimination when applying for 
insurance or employment.  Similar problems may occur if you give information yourself or agree to have your 
medical records released. 
 
Future Studies:   In the future, other investigators at NIH or outside of NIH may wish to study your stored 
samples.  When the study team shares your stored samples, they will be marked with a code, but will not have 
any identifying information on them.  Some information about you, like your gender, age, health history, or 
ethnicity may also be shared with other researchers.  Any future research studies using your samples will be 
conducted in a way that protects the rights and privacy of study participants. 
 
Study No.: IRB00108969  Emory University IRB  
IRB use only  Document Approved On: 3/18/2019  
 
 
 
VRC 313; Protocol V1 dated 09Jan2019                           Page 6 of 12                                                    ICF Vers ion: 2 Date: 03/12/2019 
PI: Srilatha Edupuganti, MD                                                                                                                                          IRB Form 12142018 Your stored samples will be used only for research and will not be sold.  The research done with your samples 
may be used to make new products in the future, but you will not get payment for such products. 
 
Making your Choice: You cannot take part in this study if you do not want us to collect or store your blood 
samples. If you agree to take part in this study, you must also agree to let us keep any of your samples for 
future research. 
 
What are the possible risks and discomforts? 
Possible  risks of injections:  Temporary stinging, pain, redness, soreness, itchiness, swelling, bruising, or a 
cut in the arm.  There is a very small chance of infection. 
 
Possible  risks of any vaccine:  Fever, chills, rash, aches and pains, nausea, headache, dizziness, and 
feeling tired and/or unwell.  These reactions are usually greatest within the first 24 hours after vaccination and 
typically last 1 to 3 days.  Over-the-counter medicine, like acetaminophen (Tylenol) or ibuprofen, may be used 
to help relieve these symptoms.   
 
Very rarely, a serious allergic reaction may o ccur shortly after any vaccination.  This is called “anaphylaxis” and 
may be life-threatening.  While you are waiting in the clinic after the vaccination, we will watch you for 
anaphylaxis.  Treatment for anaphylaxis will be given right away if it occurs.   
 
Possible  risks of blood drawing:  Pain, bleeding, bruising, feeling lightheaded, fainting, or rarely, infection at 
the site where the blood is taken. 
 
Possible  risks of WEVEE Vaccine:  The WEVEE vaccine has not been given to people before and it may 
have unknown risks or side effects.  It has been tested in mice and monkeys.  The vaccine did not have any 
severe side effects and met the safety criteria to be tested in humans.  In a study of a similar product, a 
chikungunya virus VLP vaccine was well tolerated with no reported joint pain or fever after vaccination.  No 
serious adverse events were reported.   
 
Possible  risk of aluminum hydroxide suspension:   Aluminum adjuvants have been found to be safe for 
over 60 years.  Aluminum-containing vaccines have been associated with reactions of the skin (erythema), 
bumps in the skin (subcutaneous nodules), contact hypersensitivity and small nodular skin lesions.   
 
Possible risks during pregnancy :  We do not know the possible effects of the study vaccines on a fetus or 
nursing infant.  Women who are able to become pregnant must have a negative pregnancy test before each 
study injection and agree to practice adequate birth control beginning at least 21 days before getting the first 
injection until the last study visit.  If you are pregnant, breast-feeding or want to become pregnant during the 
next 36 weeks, you cannot take part.  
 
You must also tell the clinic if you think that you are or might be pregnant during this study.  If you become 
pregnant, you will not get any more injections.  However, you will be asked to continue with follow-up visits so 
we can check your health.  You will also be asked about the outcome of your pregnancy. 
 
Possible  other risks:  The safety of the vaccine tested in this study is unknown.  It is unknown if the study 
injection will affect how you respond to any future infection with WEVEE or to any other WEVEE vaccines that 
you may get in the future. You may not donate blood at a blood bank while taking part in this study.  You may 
not donate blood for one year after your last study injection.  
 
It is possible that the researchers will learn something new during the study about the risks of being in it.  If this 
happens, they will tell you about it. Then you can decide if you want to continue to be in this study or not.  You 
may be asked to sign a new consent form that includes the new information if you decide to stay in the study. 
Study No.: IRB00108969  Emory University IRB  
IRB use only  Document Approved On: 3/18/2019  
 
 
 
VRC 313; Protocol V1 dated 09Jan2019                           Page 7 of 12                                                    ICF Vers ion: 2 Date: 03/12/2019 
PI: Srilatha Edupuganti, MD                                                                                                                                          IRB Form 12142018  
Will I benefit directly from the study?  
This study is not designed to benefit you or protect you from infection from these viruses.  Others may benefit 
in the future from the information that will be learned from the study. 
 
Will I be compensated for my time and effort? 
You will be compensated for your time and inconvenience as follows for study visits: Screening Visit (1 visit): 
$40; Vaccination Visits (2 visits): $ 80 each ; Follow Up Visits (6 visits) : $60 each. 
 
We may ask you to do extra visits to repeat lab tests or to further assess a safety concern. In those cases, you 
will receive $20 compensation for your time and inconvenience . If you do not finish the study, we will 
compensate you for the visits you have completed. You will get $ 560 total, if you complete all scheduled study 
visits.  
 
Compensation will be provided on a web based, reloadable, debit card (ClinCard) that automates 
reimbursements. The ClinCard will be provided by study staff at the initial visit (screening).  
 
All payments are made using a personal payment card. We issue this to you for free. The payment 
card is a prepaid debit card. It can be used exactly like a MasterCard. We load money onto your card 
electronically every time you need to be paid. The card scheme is run by Greenphire, an independent 
company specializing in payments for research studies and clinical trials. To issue your card, we need 
to give Greenphire some of your personal information. Banks and other financial institutions can 
access this information if they need to verify your identity when you use your card.  
 
Emory University is required by law to report any payments we make to the IRS. To do this, Emory 
University Department of Finance needs to keep your Social Security Number on file. We are asking 
you to allow us to communicate your name, address, date of birth, research study name and Social 
Security Number to Greenphire and Emory University Department of Finance. If you want to receive 
e-mail or text alerts when payments are made to you, we will ask you to provide your e-mail or phone 
number as well. All of this information will be stored on computers owned by Greenphir e.  Greenphire 
will not have access to any other information collected during this study. Full instructions about using 
your card are included when we issue it. Please ask if you have any questions or concerns about the 
card scheme.  
 
We would also like the option of compensating you in the form of cash, check or gift card if ClinCard 
accessibility is not available.  You will be asked to fill out a tax form, including your Social Security or 
Taxpayer Identification Number, in order to be reimbursed, depending on the amount and method of 
payment. Some payment methods involve mail coming to your house, which may be seen by others 
in your household. You can decline payment if you are concerned about confidentiality, or you can 
talk to the study team to see if there are other payment options. You will need to fill out a W-9 form. 
 
What are my other options? 
This study is not designed to treat or prevent any disease.  You may choose not to take part in this study.  You 
may be eligible for other studies.  
 
How will you protect my private information that you collect in this study? 
Whenever possible, a study number, rather than your name, will be used on study records.  Your name and 
other identifying information will not appear when we present or publish the study results. 
 
Study No.: IRB00108969  Emory University IRB  
IRB use only  Document Approved On: 3/18/2019  
 
 
 
VRC 313; Protocol V1 dated 09Jan2019                           Page 8 of 12                                                    ICF Vers ion: 2 Date: 03/12/2019 
PI: Srilatha Edupuganti, MD                                                                                                                                          IRB Form 12142018 Certain offices and people other than the researchers may look at study records. Government agencies and 
Emory employees overseeing proper study conduct may look at your study records.  These offices include The 
Food and Drug Administration, the Office for Human Research Protections, the sponsor, the Emory 
Institutional Review Board, the Emory Office of Research Compliance. Study funders may also look at your 
study records.   Emory will keep any research records we create private to the extent we are required to do so 
by law.  A study number rather than your name will be used on study records wherever possible.  
 
Certificate of Confidentiality 
There is a Certificate of Confidentiality from the National Institutes of Health for this Study.  The Certificate of 
Confidentiality helps us to keep others from learning that you participated in this study.  Emory will rely on the 
Certificate of Confidentiality to refuse to give out study information that identifies you.  For example, if Emory 
received a subpoena for study records, it would not give out information that identifies you. 
 
The Certificate of Confidentiality does not stop you or someone else, like a member of your family, from giving 
out information about your participation in this study.  For example, if you let your insurance company know 
that you are in this study, and you agree to give the insurance company research information, then the 
investigator cannot use the Certificate to withhold this information. This means you and your family also need 
to protect your own privacy. 
 
The Certificate does not stop Emory from making the following disclosures about you: 
 
 Giving state public health officials information about certain infectious diseases. 
 Giving law officials information about abuse of a child, elderly person or disabled person. 
 Giving out information to prevent harm to you or others. 
 Giving the study sponsor or funders information about the study, including information for an audit or 
evaluation. 
 
Storing and Sharing your Information  
To advance science, it is helpful for researchers to share information they get from studying humans by putting 
it into shared scientific databases.  Researchers can then study the information combined from many studies to 
learn even more about health and diseases.  
 
If you agree to take part in this study, some of your data will be placed into one or more scientific databases.  
We will remove identifying information like your name, address, and birth date.  The data may then be used for 
future research and shared broadly for research purposes.  Only researchers who are approved to access the 
database may be able to see and use your information. You will not get any direct benefits from future 
research that uses your data and information.  
 
In general, we will not give you any individual results from the study of the samples you give us. If we find 
something of urgent medical importance to you, we will inform you, although we expect that this will be a very 
rare occurrence. 
 
Genetic Testing 
Some genetic tests are done in research studies to see if genetic differences in people cause different types of 
immune responses.  Genetic testing will not be done in this study, but may be performed on stored samples at 
later time.  If genetic tests are done at a later time, your name and identifying information will not be on your 
samples and the results will not be in your medical record.  These tests are not used to check your health and 
we will not tell you the results.  
 
 
 
Study No.: IRB00108969  Emory University IRB  
IRB use only  Document Approved On: 3/18/2019  
 
 
 
VRC 313; Protocol V1 dated 09Jan2019                           Page 9 of 12                                                    ICF Vers ion: 2 Date: 03/12/2019 
PI: Srilatha Edupuganti, MD                                                                                                                                          IRB Form 12142018 How is my Genetic Information Protected? What are the Risks? 
The Genetic Information Nondiscrimination Act (GINA) is a federal law that generally makes it illegal for health 
insurance companies, group health plans, and most employers to discriminate against you based on your 
genetic information. This law generally will protect you in the following ways:  
• Health insurance companies and group health plans may not request your genetic information that we 
get from this research. 
• Health insurance companies and group health plans may not use your genetic information when 
making decisions regarding your eligibility or premiums.  
• Employers with 15 or more employees may not use your genetic information that we get from this 
research when making a decision to hire, promote, or fire you or when setting the terms of your 
employment. 
 
Be aware that GINA does not protect you against genetic discrimination by companies that sell life insurance, 
disability insurance, or long-term care insurance, and does not apply to employers with less than 15 
employees. 
 
In addition to GINA, the State of Georgia has laws that prohibit insurers from using genetic testing information 
for any non-treatment purpose.  However, like GINA, this state law protection has exclusions: life insurance 
policies, disability income policies, accidental death or dismemberment policies, Medicare supplement policies, 
long-term care insurance policies, credit insurance policies, specified disease policies, hospital indemnity 
policies, blanket accident and sickness policies, franchise policies issued on an insurance policy written as a 
part of workers’ compensation equivalent coverage, or other similar limited accident and sickness policies.  
 
Privilege  
In the State of Georgia, in some circumstances your genetic information has may have special legal 
protections cal led “privilege.” This means that the information cannot be used as evidence in a court. By 
allowing us to use and disclose your genetic information for this research study along with other information 
about you that genetic information used in the research may no longer have that legal protection. Other 
protections described in this form will still apply. There are also other confidentiality protections for research 
data in general under Georgia state law.    
 
Who will monitor the study?  
This study will be monitored by a group of physicians and scientists associated with the NIH.  This group will 
review the study information and will pay close attention to any reactions.  If there are serious side effects, 
study injections may be delayed or canceled. 
 
Your research study charts may be reviewed by the IND Sponsor representatives.   
 
Conflict of Interest 
The NIH developed the investigational product being used in this research study.  The results of this study 
could play a role in whether the FDA will approve the study product for sale at some time in the future.  If 
approved, the future sale of the study product could lead to payments to NIH and some NIH  scientists.  By U.S. 
law, government scientists are required to get such payments for their inventions.  You will not get any money 
from the development or sale of the product.   
 
Medical Record 
If you have been an Emory Healthcare patient before, then you already have an Emory Healthcare medical 
record.  If you have never been an Emory Healthcare patient, you do not have one.   An Emory Healthcare 
medical record will be made for you if an Emory provider or facility gives you any services or procedures for 
this study.   
 
Study No.: IRB00108969  Emory University IRB  
IRB use only  Document Approved On: 3/18/2019  
 
 
 
VRC 313 ; Protocol V1 dated 09Jan2019                            Page 10 of 12                                                    ICF Version: 2 Date: 
03/12/2019  
PI: Srilatha Edupuganti, MD                                                                                                                                          IRB Form 12142018  We will take reasonable steps to keep copies of this form out of Emory Healthcare’s medical r ecords system.  
If we aren’t successful in keeping these forms out, despite our efforts, we will take steps to remove them.  If 
they cannot be removed, we will take steps to limit access to them.  
 
Emory Healthcare may create study information about you th at can help with your care.  For example, the 
results of study tests or procedures.  These study results will be put in your Emory Healthcare medical record. 
Anyone who has access to your medical records will be able to have access to all the study informa tion placed 
there.  The confidentiality of the study information in your medical record will be protected by laws like the 
HIPAA privacy rule.  State and federal laws may not protect the research information from disclosure.  We will 
ask for your authoriza tion if we need to obtain any information from your medical record.  
 
We will also keep a separate research record of all study tests and procedures that we will use for research 
purposes.  For this study, those items include: safety laboratory tests and pregnancy tests. This research 
record will not be a part of your medical record.  
 
Tests and procedures done at non -Emory places may not become part of your Emory medical record. Also, if 
you decide to be in this study, it is up to you to let your other hea lth providers know.  
 
In Case of Injury  
If you believe you have become ill or injured from this research, you should contact Dr. Edupuganti  at 
telephone number . You should also let any health care provider who treats you know that you 
are in a research study.   
 
If you get ill or injured from being in the study, Emory will help you to get medical treatment. We will provide 
emergency treatment for any immediate reactions to the study products at the Hope Clinic. Neither Emory nor 
the sponsor will pay for your medical treatment  you may receive outside of the Hope Clinic. Your insurer will be 
billed for your treatment costs.  If you do not have insurance, or if your insurance does not pay, then you will 
have to pay these costs.    
 
Emory and the spo nsor have not, however, set aside any money to pay you if you are injured as a result of 
being in this study or to pay for this medical treatment. For Emory, the only exception is if it is proven that your 
injury or illness is directly caused by the neglig ence of an Emory employee. “Negligence” is the failure to follow 
a standard duty of care. You do not give up any legal rights you may have by being in this study, including any 
right to bring a claim for negligence.  
 
Costs  
There will be  no costs to you fo r participating in this study, other than basic expenses like transportation . You 
will not be charged for any of the research activities.  If the study procedures result in any medical 
complications that would not fall under “injury” as discussed above, the  cost of treatment for those 
complications may be charged to you or your insurance.   
 
Withdrawal from the Study  
Your participation in this study is completely voluntary.  You can choose to stop taking part in the study at any 
time.  There is no penalty or  loss of benefits for choosing to leave the study.  
 
If you get the first injection but not the second, we still want you to continue with all planned follow -up visits 
until the end of the study.  It is important that we continue to check your health even i f you do not get the 
second vaccination.  
 

Study No.: IRB00108969  Emory University IRB  
IRB use only  Document Approved On: 3/18/2019  
 
 
 
VRC 313 ; Protocol V1 dated 09Jan2019                            Page 11 of 12                                                    ICF Version: 2 Date: 
03/12/2019  
PI: Srilatha Edupuganti, MD                                                                                                                                          IRB Form 12142018  The researchers also have the right to stop your participation in this study without your consent for any reason, 
especially if they believe it is in your best interest or if you were to object to any future change s that may be made 
in the study plan.   
 
These are the expected reasons why the researchers may stop your participation:  
 You do not keep appointments or follow study procedures.  
 You get a serious illness that needs ongoing medical care.  
 You need to get tre atment with a medication that affects your immune system (such as a steroid like 
prednisone).  
 You enroll in another research study at the same time you are in this study.  
 You become pregnant.  
 The study is stopped by regulatory agencies, the study sponsor  or study investigators. If this happens, we 
will tell you why.  
 
Contact Information  
Contact Dr. Sri Edupuganti at : 
 if you have any questions about this study or your part in it,   
 if you feel you have had a research -related injury or a bad r eaction to the study vaccine,  or 
 if you have questions, concerns or complaints about the research  
 
Contact the Emory Institutional Review Board -- -- : 
 if you have questions ab out your rights as a research participant.  
 if you have questions, concerns or complaints about the research.  
 You may also let the IRB know about your experience as a research participant through our Research 
Participant Survey at  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Study No.: IRB00108969  Emory University IRB  
IRB use only  Document Approved On: 3/18/2019  
 
 
 
VRC 313; Protocol V1 dated 09Jan2019                           Page 12 of 12                                                    ICF Vers ion: 2 Date: 
03/12/2019 
PI: Srilatha Edupuganti, MD                                                                                                                                          IRB Form 12142018  
Consent  
 
If you decide to participate in this study, your samples will be stored for future use. This is a 
requirement for participation in the study. However, the study team wants to make sure that you are 
aware of this and that you agree to have your samples stored. Please initial one of the options below 
to indicate your choice: 
 
______ Yes, I agree to let the sponsor store my samples. 
 (Initial)  
 
______ No, I do not agree to let the sponsor store my samples.  
 (Initial)  
 
 
TO BE FILLED OUT BY SUBJECT ONLY 
Please print  your name, sign, and date below if you agree to be in this research study. By signing this consent 
and authorization form, you will not give up any of your legal rights. We will give you a copy of the signed form to 
keep. 
 
  
Name of Subject  
 
         __________        ____:____ am / pm  
Signature of Subject (18 or older and able to consent) Date                  Time 
 
 
TO BE FILLED OUT BY STUDY TEAM ONLY  
 
__________________________________________________________  
Name of Person Conducting Informed Consent Discussion 
 
         __________        ____:____ am / pm  
Signature of Person Conducting Informed Consent Discussion Date                   Time 